Document:

Exhibit 10.5

 

TIER REIT, INC.

 

RESTRICTED STOCK AWARD AGREEMENT

 

Name of the Grantee: [    ] (the “Grantee”)

No. of Shares of Restricted Stock Awarded: [          ]

Grant Effective Date: [     ], 201

 

RECITALS

 

A.                                    The Grantee is [a/an] [non-employee director/officer] of TIER REIT, Inc. (the “Company”).

 

B.                                    Pursuant to the Company’s 2015 Equity Incentive Plan (as may be amended and supplemented from time to time, the “Plan”), the Company hereby grants to the Grantee the number of shares of Restricted Stock of the Company, subject to the terms and conditions set forth herein.  Unless otherwise indicated, capitalized terms used herein but not defined shall have the meanings given to those terms in the Plan.

 

NOW, THEREFORE, the Company and the Grantee agree as follows:

 

1.                                      Grant of Restricted Stock.  The Company hereby grants the Grantee the number of shares of Restricted Stock of the Company specified above, subject to the following terms and conditions and subject to the provisions of the Plan.  The Plan is hereby incorporated herein by reference as though set forth herein in its entirety.

 

2.                                      Restrictions and Conditions.  The Restricted Stock awarded pursuant to this Agreement and the Plan shall be subject to the following restrictions and conditions:

 

(i)                                     Subject to clause (iv) below, the period of restriction with respect to the shares of Restricted Stock granted hereunder (the “Restriction Period”) shall begin on the Grant Effective Date and lapse on the following schedule, provided that termination of the Grantee’s [employment/service as director] has not occurred prior to the applicable date restrictions lapse:

 

 

	
Date
   Restrictions Lapse
    	
 
    	
Number of
   Shares Becoming Vested
    	
 
    	
Cumulative
   Percentage Vested
    	
 
    
	
[   ]
    	
 
    	
[   ]   ([25]%)
    	
 
    	
[25]%
    	
 
    
	
[   ]
    	
 
    	
[   ]   ([25]%)
    	
 
    	
[50]%
    	
 
    
	
[   ]
    	
 
    	
[   ]   ([25]%)
    	
 
    	
[75]%
    	
 
    
	
[   ]
    	
 
    	
[  ] ([25]%)
    	
 
    	
[100]%
    	
 
    

 

Subject to the provisions of the Plan and this Agreement, during the Restriction Period, the Grantee shall not be permitted voluntarily or involuntarily to sell, transfer, pledge, anticipate, alienate, encumber or assign the shares (or have such shares attached or garnished).

 

(ii)                                  Except as provided in the foregoing clause (i) or in the Plan, the Grantee shall have, in respect of the shares of Restricted Stock, all of the rights of a stockholder of the Company, including the right to vote the shares of Restricted Stock and the right to receive dividends if, as and when paid.

 

(iii)                               Subject to clause (iv) below, upon termination of the Grantee’s [employment/service as a director], then all shares of Restricted Stock still subject to restriction shall thereupon, and with no further action, be forfeited by the Grantee.

 

(iv)                              Notwithstanding any other term or provision of this Agreement, upon (A)  termination of the Grantee’s [employment/service as director] as a result of the Grantee’s death or disability or (B) a Sale Event (regardless of whether or not a termination of the Grantee’s [employment/service as director] has occurred), during the Restriction Period, then the Restriction Period will immediately lapse on all Restricted Stock granted to the Grantee that have not previously been forfeited.

 

(v)                                 Notwithstanding anything to the contrary in this Section 2, to the extent the Grantee is a party to another agreement or arrangement with the Company that provides accelerated vesting of the shares of Restricted Stock or all equity awards in general in the event of certain types of employment terminations, a Sale Event, or any other applicable vesting-related events or provides more favorable vesting provisions than provided for in this Agreement, the more favorable vesting terms of such other agreement or arrangement shall control.

 

3.                                      Incorporation of Plan; Interpretation by Administrator.  This Agreement is subject in all respects to the terms, conditions, limitations and definitions contained in the Plan.  In the event of any discrepancy or inconsistency between this Agreement and the Plan, the terms and conditions of the Plan shall control.  The Administrator may make such rules and regulations and establish such procedures for the administration of this Agreement as it deems appropriate.  Without limiting the generality of the foregoing, the Administrator may interpret the Plan and this Agreement, with such interpretations to be conclusive and binding on all persons and otherwise accorded the maximum deference permitted by law, provided that the Administrator’s interpretation shall not be entitled to deference on and after a Sale Event except to the extent that

 

2

 

such interpretations are made exclusively by members of the board of directors of the Company or relevant committee thereof, who are individuals who served as members of such board or committee, as applicable, before the Sale Event and take any other actions and make any other determinations or decisions that it deems necessary or appropriate in connection with the Plan, this Agreement or the administration or interpretation thereof.  In the event of any dispute or disagreement as to interpretation of the Plan or this Agreement or of any rule, regulation or procedure, or as to any question, right or obligation arising from or related to the Plan or this Agreement, the decision of the Administrator, except as provided above, shall be final and binding upon all persons.

 

4.                                      Legend.  The records of the Company and any other documentation evidencing the shares of Restricted Stock shall bear an appropriate legend, as determined by the Company in its sole discretion, to the effect that such shares of Restricted Stock are subject to restrictions as set forth herein, in the Plan and in this Agreement.

 

5.                                      Withholding and Taxes.  No later than the date as of which an amount first becomes includible in the gross income of the Grantee for income tax purposes or subject to the Federal Insurance Contributions Act withholding with respect to the shares of Restricted Stock granted hereunder, the Grantee will pay to the Company or, if appropriate, any of its Subsidiaries, or make arrangements satisfactory to the Administrator regarding the payment of, any United States federal, state or local or foreign taxes of any kind required by law to be withheld with respect to such amount.  The obligations of the Company under this Agreement will be conditional on such payment or arrangements, and the Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment otherwise due to the Grantee.  The Grantee may elect to have the required minimum tax withholding obligation satisfied, in whole or in part, by (i) authorizing the Company to withhold from shares of Restricted Stock to be issued, or (ii) transferring to the Company, a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due.

 

6.                                      Amendment; Modification.  This Agreement may only be modified or amended in a writing signed by the parties hereto, provided that the Grantee acknowledges that the Plan may be amended or discontinued in accordance with Section 19 thereof and that this Agreement may be amended or canceled by the Administrator, on behalf of the Company, for the purpose of satisfying changes in law or for any other lawful purpose, so long as no such action shall adversely affect the Grantee’s rights under this Agreement without the Grantee’s written consent.  No promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, with respect to the subject matter hereof, have been made by the parties which are not set forth expressly in this Agreement.  The failure of the Grantee or the Company to insist upon strict compliance with any provision of this Agreement, or to assert any right the Grantee or the Company, respectively, may have under this Agreement, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.

 

7.                                      Complete Agreement.  This Agreement (together with those agreements and documents expressly referred to herein, for the purposes referred to herein) embody the complete and entire agreement and understanding between the parties with respect to the subject matter

 

3

 

hereof, and supersede any and all prior promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, which may relate to the subject matter hereof in any way.

 

8.                                      No Obligation to Continue Employment or Other Service Relationship.  Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue to have the Grantee provide services to it or to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate its service relationship with the Grantee or the employment of the Grantee at any time.

 

9.                                      No Limit on Other Compensation Arrangements.  Nothing contained in this Agreement shall preclude the Company from adopting or continuing in effect other or additional compensation plans, agreements or arrangements, and any such plans, agreements and arrangements may be either generally applicable or applicable only in specific cases or to specific persons.

 

10.                               Severability.  If any term or provision of this Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially altering the purpose or intent of this Agreement and the grant of shares of Restricted Stock hereunder, such provision shall be stricken as to such jurisdiction and the remainder of this Agreement and the award hereunder shall remain in full force and effect).

 

11.                               Law Governing.  THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW WHICH COULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF TEXAS.

 

12.                               Headings.  Section, paragraph and other headings and captions are provided solely as a convenience to facilitate reference.  Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of this Agreement or any term or provision hereof.

 

13.                               Notices.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

14.                               Counterparts.  This Agreement may be executed in two or more separate counterparts, each of which shall be an original, and all of which together shall constitute one and the same agreement.

 

15.                               Successors and Assigns.  The rights and obligations created hereunder shall be binding on the Grantee and his heirs and legal representatives and on the successors and assigns of the Company.

 

4

 

[Signature Page Follows]

 

5

 

IN WITNESS WHEREOF, the undersigned have caused this Award to be executed on the [             ] day of [                   ], 201  .

 

	
 
    	
TIER   REIT, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Title:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Grantee
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name:
    
	
 
    	
 
    
	
 
    	
Address:
    

 

6prtk-ex105_86.htm

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Exhibit 10.5

LOAN AND SECURITY AGREEMENT 

THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2015 and is entered into by and among (a) (i) PARATEK PHARMACEUTICALS, INC., a Delaware corporation (“Inc.”), (ii) PARATEK PHARMA, LLC, a Delaware limited liability company (“LLC”), and (iii) each of its Qualified Subsidiaries that executed a Joinder Agreement in accordance with the terms hereof (hereinafter collectively referred to as the “Borrower”), (b) (i) HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership, (ii) HERCULES TECHNOLOGY III, L.P., a Delaware limited partnership, and (iii) the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lender”) and (c) HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent for itself and the Lender (in such capacity, the “Agent”).  

RECITALS

A.Borrower has requested Lender to make available to Borrower Term Loan Advances in an aggregate principal amount of up to Forty Million Dollars ($40,000,000) (the “Maximum Term Loan Amount”); 

B.Lender is willing to make the Term Loan Advances on the terms and conditions set forth in this Agreement.

AGREEMENT

NOW, THEREFORE, Borrower, Agent and Lender agree as follows:

SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION

1.1Unless otherwise defined herein, the following capitalized terms shall have the following meanings:

“1934 Act” means the Securities Exchange Act of 1934, as amended.

 “Account Control Agreement(s)” means any agreement entered into by and among Agent, Borrower and a third party Bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which perfects Agent’s first priority security interest in the subject account or accounts.

 “ACH Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H.

“Acquisition” means the purchase or acquisition by Borrower or any Qualified Subsidiary of (a) all or any substantial portion of the assets of, or a line of business, division or operating group of, another Person or (b) at least a majority of the stock or equity interests of another Person, in each case whether or not involving a merger or consolidation with such other Person.

 

 

“Advance(s)” means a Term Loan Advance.

“Advance Date” means the funding date of any Advance.

“Advance Request” means a request for an Advance submitted by Borrower to Agent in substantially the form of Exhibit A.

“Affiliate” means (a) any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in question, (b) any Person directly or indirectly owning, controlling or holding with power to vote ten percent (10%) or more of the outstanding voting securities of another Person, (c) any Person ten percent (10%) or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities, or (d) any Person related by blood or marriage to any Person described in subsection (a), (b) or (c) of this paragraph.  As used in the definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise.

“Agent” has the meaning given to it in the preamble to this Agreement.

“Agreement” means this Loan and Security Agreement, as amended from time to time.

“Amortization Date” means April 1, 2018. 

“Assignee” has the meaning given to it in Section 11.13.

“Board” means Borrower’s board of directors or any subcommittee thereof, as applicable.

“Borrower Products” means all products, software, service offerings, technical data or technology currently being designed, manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed or distributed by Borrower since its incorporation.

“Business Day” means any day other than Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business.

 “Cash” means all cash, cash equivalents and liquid funds.

“Change in Control” means any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the 1934 Act, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the 1934 Act) of more than thirty-five percent (35%) of the equity interests of Inc. entitled to vote for members of its Board on a fully diluted basis (and taking into account all such securities that such person or group has the right to acquire pursuant to any option right). 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

“Claims” has the meaning given to it in Section 11.10.

“Clinical Assets” means Sarecycline.

“Closing Date” means the date of this Agreement.

“Collateral” means the property described in Section 3.

“Common Stock” means the Common Stock, $0.001 par value per share, of Borrower.

“Confidential Information” has the meaning given to it in Section 11.12.

“Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any Indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business.  The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.

 “Copyright License” means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

“Copyrights” means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof, or of any other country.

 “Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit.

“Draw Period” means the period commencing upon the Closing Date and ending on the earlier to occur of (a) the Draw Period End Date, and (b) an Event of Default.

“Draw Period End Date” means June 30, 2016, provided however that upon the occurrence of the Draw Period Extension Event, the Draw Period End Date shall mean December 31, 2016.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

“Draw Period Extension Event” means confirmation by Agent and Lender (not to be unreasonably withheld or delayed), after the Closing Date, but on or prior to June 30, 2016, that the aggregate original principal amount of all Term Loan Advances requested by Borrower equals or exceeds Twenty Million Dollars ($20,000,000).  

“Domestic Subsidiary” means any Subsidiary that is not a Foreign Subsidiary or an Excluded Subsidiary.

“Due Diligence Fee” means Fifty Thousand Dollars ($50,000), which fee is due to Lender on or prior to the Closing Date, and shall be deemed fully earned on such date regardless of the early termination of this Agreement.

“End of Term Charge” shall have the meaning assigned to such term in Section 2.5.

“Eligible Foreign Subsidiary” means any Foreign Subsidiary whose execution of a Joinder Agreement would not result in a material adverse tax consequence to Borrower.

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.

“Event of Default” has the meaning given to it in Section 9.

“Excluded Account” means any Account (including, for the avoidance of doubt, any cash, cash equivalents or other property contained therein) to the extent, and for so long as, such Account is pledged and used exclusively to secure performance of obligations arising under clause (vi) of the defined term “Permitted Liens”, and whether such pledge is by escrow or otherwise.

“Excluded Property” means (i) Excluded Accounts (and any assets contained therein); (ii) more than 65% of the presently existing and hereafter arising issued and outstanding shares of capital stock owned by Borrower of any Foreign Subsidiary (other than a Foreign Subsidiary that has executed a Joinder Agreement pursuant to the terms hereof) which shares entitle the holder thereof to vote for directors or any other matter; (iii) equipment financed by capital leases or purchase money financing, products, proceeds and insurance proceeds of the foregoing, but only to the extent and for so long as the agreements under which the equipment is financed prohibit granting a security interest therein to Lender; and (iv) rights held under a license that are not assignable by their terms without the consent of the licensor thereof (but only to the extent such restriction on assignment is enforceable under applicable law).  

“Excluded Subsidiary” means Paratek Securities Corporation, a Massachusetts securities corporation, which is a Subsidiary of Borrower that has applied or is in the process of applying to be classified as a “security corporation” under Massachusetts General Laws Ch. 63, Section 38B(a), as amended, supplemented and/or modified.

“Facility Charge” means eighty-five hundredths of one percent (0.85%) of the Maximum Term Loan Amount, which is Three Hundred Forty Thousand Dollars ($340,000).

“Financial Statements” has the meaning given to it in Section 7.1.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

“First Term Loan Advance” shall have the meaning assigned to such term in Section 2.1(a).

“Foreign Subsidiary” means any Subsidiary other than a Subsidiary organized under the laws of any state within the United States.

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time.

“Inc.” has the meaning given to it in the preamble to this Agreement.

“Indebtedness” means indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within one hundred eighty (180) days), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations.

“Ineligible Subsidiary” means any Domestic Subsidiary or Foreign Subsidiary which has assets of at least One Million Dollars ($1,000,000) and generates annual revenue in an amount less than One Million Dollars ($1,000,000), in each case determined as of the most recent fiscal year end; provided that at no time shall the each of assets and annual revenue (in each case determined as of the most recent fiscal year end) of all Ineligible Subsidiaries, taken as a whole, exceed Five Million Dollars ($5,000,000), in all cases determined in accordance with GAAP.    

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

“Intellectual Property” means all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works; Borrower’s applications therefor and reissues, extensions, or renewals thereof; and Borrower’s goodwill associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith.

“Investment” means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person.

“Joinder Agreements” means for each Qualified Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit G.

“LLC” has the meaning given to it in the preamble to this Agreement.

“Lender” has the meaning given to it in the preamble to this Agreement.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 “License” means any Copyright License, Patent License, Trademark License or other license of rights or interests.

“Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest.

“Loan” means the Advances made under this Agreement.

“Loan Documents” means this Agreement, the Notes (if any), the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all UCC Financing Statements, the Warrants, any subordination agreement, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.

“Material Adverse Effect” means a material adverse effect upon: (i) the business, operations, properties, assets or financial condition of Borrower and its Subsidiaries taken as a whole; or (ii) the ability of Borrower to perform or pay the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Agent or Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Agent’s Liens on the Collateral or the priority of such Liens.

“Maximum Term Loan Amount” shall have the meaning assigned to such term in the preamble to this Agreement. 

“Maximum Rate” shall have the meaning assigned to such term in Section 2.2.

 “Note(s)” means a promissory note or promissory notes to evidence Lender’s Loans, substantially in the form of Exhibit B.

“Patent License” means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest.

“Patents” means all letters patent of, or rights corresponding thereto, in the United States or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any other country.

“PCAOB” is the public company accounting oversight board.

“Permitted Acquisition” means an Investment consisting of an Acquisition by the Borrower or any Subsidiary, provided that (a) no Event of Default has occurred and is continuing or would immediately result from such Acquisition, (b) in the case of an Acquisition of the equity interests of another Person, the board of directors (or other comparable governing body) of such other Person shall have duly approved such Acquisition, and (c) the aggregate consideration (including assumption of Indebtedness) with respect to such Permitted Acquisition, taken together with all other Permitted Acquisitions consummated during the term of this 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Agreement, but excluding the net cash proceeds of any issuance of equity securities received after the Closing Date, shall not exceed Seven Million Five Hundred Thousand Dollars ($7,500,000) in the aggregate.

 “Permitted Indebtedness” means: (i) Indebtedness of Borrower in favor of Lender or Agent arising under this Agreement or any other Loan Document; (ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to Five Hundred Thousand Dollars ($500,000) outstanding at any time secured by a Lien described in clause (vii) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed the cost of the Equipment financed with such Indebtedness; (iv) Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit and cash management services (including credit cards, debit cards and similar instruments) that are secured by Cash and issued on behalf of Borrower or a Subsidiary thereof in an amount not to exceed Seven Hundred Fifty Thousand Dollars ($750,000) at any time outstanding, (viii) Indebtedness secured by a Lien described in clause (xi) of the defined term “Permitted Liens”; (ix) other unsecured Indebtedness in an amount not to exceed Two Million Dollars ($2,000,000) at any time outstanding, (ix) intercompany Indebtedness that constitutes a Permitted Investment; (x) Permitted Royalty Backed Indebtedness; and (xi) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be.

“Permitted Investment” means: (i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof, (b) commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (c) certificates of deposit issued by any bank with assets of at least Five Hundred Million Dollars ($500,000,000) maturing no more than one year from the date of investment therein, (d) money market accounts, and (e) such other Investments as are described in the Board-approved investment policy guidelines delivered to Agent prior to the Closing Date; (iii) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; (iv) repurchases of stock from current or former employees, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed Two Hundred Fifty Thousand Dollars ($250,000) in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases; (v) Investments accepted in connection with Permitted Transfers; (vi) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (vii) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, provided that this subparagraph (vii) shall not apply to Investments of Borrower in any Subsidiary; (viii) Investments consisting of loans not involving the net transfer on a 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by Borrower’s Board; (ix) Investments consisting of travel advances, relocation loans, and other loans advanced (or guarantees thereof) to employees, officers and directors in the ordinary course of business; (x) Investments in Domestic Subsidiaries, provided that each such Domestic Subsidiary has entered into a Joinder Agreement and executed such other documents as shall have been reasonably requested by Agent in connect with same; (xi) Investments in Foreign Subsidiaries approved in advance in writing by Agent; (xii) joint ventures or strategic alliances in the ordinary course of Borrower’s business, provided that any cash Investments by Borrower or any of its Subsidiaries in connection therewith do not exceed One Hundred Thousand Dollars ($100,000) in the aggregate in any fiscal year; (xiii) Investments consisting of Permitted Acquisitions; (xiv) Investments made in the Excluded Subsidiary; (xv) Investments in Subsidiaries not in excess of the amounts set forth in the Board-approved projections or budget (as applicable) and, in each case made to support ordinary, necessary, and substantially concurrent clinical development and related expenses of Inc. and its Subsidiaries; (xvi) additional Investments that do not exceed One Million Dollars ($1,000,000) in the aggregate; and (xvii) Investments in any Person, which is not a Borrower under this Agreement, made in connection with a Permitted Royalty Backed Indebtedness Transaction.

“Permitted Liens” means any and all of the following: (i) Liens in favor of Agent or Lender; (ii) Liens existing on the Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in accordance with GAAP (to the extent required thereby); (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; (vi) deposits to secure the performance of obligations (including by way of deposits to secure letters of credit issued to secure the same) under commercial supply and/or manufacturing agreements in the ordinary course of business and the following deposits, to the extent made in the ordinary course of business:  deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) Liens on Equipment or software or other intellectual property constituting purchase money Liens and Liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness”;  (viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses and sublicenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor; (x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

other property or assets); (xii) statutory and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiv) (A) Liens on Cash securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness and (B) security deposits in connection with real property leases, the combination of (A) and (B) in an aggregate amount not to exceed One Hundred Thousand Dollars ($100,000) at any time; (xv) sales, transfers, licenses, sublicenses, leases, subleases or other dispositions of assets permitted by Section 7.8 and, in connection therewith, customary rights and restrictions contained in agreements relating to such transactions pending the completion thereof or during the term thereof, and any option or other agreement to sell, transfer, license, sublicense, lease, sublease or dispose of an asset permitted by Section 7.8, (xvi) Liens on assets of any Person which is not a Borrower under this Agreement pledged in connection with a Permitted Royalty Backed Indebtedness Transaction; and (xvii) Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type described in clauses (i) through (xvi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase.

“Permitted Royalty Backed Indebtedness” means Indebtedness of a Person, which is not a Borrower (on terms customary for transactions of this nature) under this Agreement (other than the Permitted Royalty Stock Pledge or the Permitted Royalty Guaranty) incurred from to time that is secured solely by the Permitted Royalty Stock Pledge, royalties (or rights therein or related thereto), rights to payment under royalties, licenses and the proceeds thereof solely with respect to such Person’s Clinical Asset.

“Permitted Royalty Backed Indebtedness Transaction” means a transaction pursuant to which Permitted Royalty Backed Indebtedness is incurred and the net cash proceeds of such transaction are immediately deposited into an account in the name of (i) Borrower and subject to an Account Control Agreement or (ii) Excluded Subsidiary.

“Permitted Royalty Guaranty” means an unsecured guaranty (other than the Permitted Royalty Stock Pledge) by Borrower in favor of the SPE Lender; provided however, in no event shall any cash payment be made on such guaranty while any of the Secured Obligations (other than inchoate indemnity obligations) remain outstanding.

“Permitted Royalty Stock Pledge” means a pledge of the stock of the SPE by the Borrower to the SPE Lender pursuant to the Permitted Royalty Backed Indebtedness Transaction. 

“Permitted Transfers” means (i) sales, transfers or other dispositions of Inventory in the ordinary course of business, (ii) licenses, sublicenses and similar arrangements for the use of Intellectual Property and related assets in the ordinary course of business and other licenses and sublicenses that could not result in a legal transfer of title of the licensed property, (iii) transfers expressly permitted under Section 7.5, 7.6 or 7.7, (iv) dispositions of worn-out, obsolete or 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

surplus Equipment at fair market value in the ordinary course of business, (v) transfers by and among the Borrower and any of its Subsidiaries, provided that such Subsidiary has entered into a Joinder Agreement and such other documents as shall be reasonably requested by Agent; (vi) transfers to Subsidiaries in connection with clause (xv) of “Permitted Investments”; (vii) other transfers of assets having a fair market value of not more than Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate in any fiscal year; and (vii) transfer of the Clinical Asset and any royalties (or rights therein or related thereto), rights to payment under royalties, licenses and the proceeds thereof to an SPE.

 “Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government.

“Prepayment Charge” shall have the meaning assigned to such term in Section 2.4. 

“Prime Rate” means the “prime rate” as reported in The Wall Street Journal, and if not reported, then the prime rate most recently reported in The Wall Street Journal. 

 “Qualified Subsidiary” means any direct or indirect Domestic Subsidiary or Eligible Foreign Subsidiary but which may, in Borrower’s sole discretion, exclude any Ineligible Subsidiary.

“Receivables” means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto.

“Required Lenders” means at any time, the holders of more than fifty percent (50%) of the aggregate unpaid principal amount of the Term Loan Advances then outstanding.

 “SBA” shall have the meaning assigned to such term in Section 7.16.

“SBIC” shall have the meaning assigned to such term in Section 7.16.

“SBIC Act” shall have the meaning assigned to such term in Section 7.16

“SEC” means the Securities and Exchange Commission.

“Second Term Loan Advance” and “Second Term Loan Advances” shall have the meaning assigned to such terms in Section 2.1(a).

 “Second Term Loan Advance Amount” means (a) Forty Million Dollars ($40,000,000), minus (b) the original principal amount of the First Term Loan Advance.

“Secured Obligations” means Borrower’s obligations under this Agreement and any Loan Document (other than the Warrants), including any obligation to pay any amount now owing or later arising (including, without limitation, the End of Term Charge and the Prepayment Charge).

“Securities Act” means the Securities Act of 1933, as amended.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

“SPE” means any Subsidiary formed for the sole purpose of effectuating a Permitted Royalty Backed Indebtedness Transaction and whose sole assets consist of the Clinical Asset and any royalties (or rights therein or related thereto), rights to payment under royalties, licenses and the proceeds thereof which are the subject of the Permitted Royalty Back Indebtedness Transaction.

“SPE Lender” means the lender(s) under the Permitted Royalty Backed Indebtedness Transaction. 

“Subordinated Indebtedness” means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Agent in its sole discretion.

“Subsequent Financing” means the sale and issuance by Borrower, after the date hereof, of its equity securities to one or more investors for cash for financing purposes in a transaction or series of related transactions not registered under the Securities Act of 1933, as amended, pursuant to a broadly marketed offer to multiple investors and in which Borrower receives aggregate cash proceeds of at least Ten Million Dollars ($10,000,000).

 “Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls fifty percent (50%) or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto.

“Term Commitment” means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrower in a principal amount not to exceed the amount set forth under the heading “Term Commitment” opposite such Lender’s name on Schedule 1.1.  

“Term Loan Advance” and “Term Loan Advances” shall have the meaning assigned to such terms in Section 2.1(a). 

“Term Loan Interest Rate” means for any day, a floating per annum rate equal to the greater of either (a) eight and one half of one percent (8.5%), or (b) the sum of (i) eight and one half of one percent (8.5%), plus (ii) the Prime Rate minus five and three quarters of one percent (5.75%).   

“Term Loan Maturity Date” means September 1, 2020.

“Trademark License” means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 

“Trademarks” means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof.

“UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent’s 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.  

 “Warrants” means (i) the Warrant Agreement dated as of even date hereof by and between Hercules Technology II, L.P. and Borrower, and (ii) the Warrant Agreement dated as of even date hereof by and between Hercules Technology III, L.P. and Borrower, in each case, as may be amended, restated or modified from time to time. 

Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement.  Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.

SECTION 2. THE LOAN

2.1Term Loan.

(a)Advances.  Subject to the terms and conditions of this Agreement, Lender will severally (and not jointly) make, in an amount not to exceed its respective Term Commitment, and Borrower agrees to draw, one (1) Term Loan Advance in an amount of at least Fifteen Million Dollars ($15,000,000) on the Closing Date (the “First Term Loan Advance”).  Subject to the terms and conditions of this Agreement, during the Draw Period, Lender will severally (and not jointly) make, in an amount not to exceed its respective Term Commitment, and Borrower may request, additional Term Loan Advances in an aggregate amount of up to the Second Term Loan Advance Amount (each, a “Second Term Loan Advance” and collectively, the “Second Term Loan Advances”).  The First Term Loan Advance and the Second Term Loan Advances are hereinafter referred to singly as the “Term Loan Advance” and collectively as the “Term Loan Advances.”  Each Term Loan Advance shall be in a minimum amount of at least Ten Million Dollars ($10,000,000).  The aggregate outstanding Term Loan Advances shall not exceed the Maximum Term Loan Amount.  Proceeds of any Term Loan Advance shall be deposited into an account that is subject to a first priority perfected security interest in favor of Agent perfected by an Account Control Agreement.

(b)Advance Request.  To obtain a Term Loan Advance, Borrower shall complete, sign and deliver to Agent an Advance Request (at least three (3) Business Days before the Advance Date other than the Closing Date, which shall be at least one (1) Business Day).  Lender shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

(c)Interest.  The principal balance of each Term Loan Advance shall bear interest thereon from such Advance Date at the Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed.  The Term Loan Interest Rate will float and change on the day the Prime Rate changes from time to time.  

(d)Payment.  Borrower will pay interest on each Term Loan Advance on the first (1st) Business Day of each month, beginning the month after the Advance Date.  Commencing on the Amortization Date, and continuing on the first (1st) Business Day of each month thereafter, until the Secured Obligations are repaid, Borrower shall repay the aggregate principal balance of Term Loan Advances that are outstanding on the day immediately preceding the Amortization Date in equal monthly installments of principal and interest (mortgage style) based upon an amortization schedule equal to thirty (30) consecutive months.  The entire principal balance of the Term Loan Advances and all accrued but unpaid interest hereunder, and all other Secured Obligations with respect to the Term Loan Advances, shall be due and payable on Term Loan Maturity Date.  Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to Borrower’s account as authorized on the ACH Authorization (i) on each payment date of all periodic obligations payable to Lender under each Term Advance and (ii) after prior notice to Borrower, out-of-pocket legal fees and costs incurred by Agent or Lender in connection with Section 11.11 of this Agreement. Once repaid, a Term Loan Advance or any portion thereof may not be reborrowed.

2.2Maximum Interest.  Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”).  If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows:  first, to the payment of the Secured Obligations consisting of the outstanding principal amount of the Term Loan Advances; second, after all principal is repaid, to the payment of Lender’s accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.  

2.3Default Interest.  In the event any payment is not paid on the scheduled payment date, an amount equal to five percent (5%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.1(c), plus five percent (5%) per annum.  In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(c) or Section 2.3, as applicable.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

2.4Prepayment.  At its option upon at least seven (7) Business Days prior notice to Agent, Borrower may prepay all or any portion, of the outstanding Advances (in increments of Five Million Dollars ($5,000,000)) by paying the entire principal balance (or portion thereof), all accrued and unpaid interest with respect to the principal balance being prepaid, together with a prepayment charge equal to the following percentage of the Advance amount: subject to the second succeeding sentence, if such Advance amounts are prepaid prior to April 1, 2018, two percent (2.0%) of the then outstanding principal amount of the Advances being prepaid; and on or after April 1, 2018, zero percent (0.0%) of the then outstanding principal amount of the Advances being prepaid (each, a “Prepayment Charge”).  Borrower agrees that the Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances. Upon the occurrence of a Change in Control, Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and all unpaid Agent’s and Lender’s fees and expenses accrued to the date of the repayment (including the End of Term Charge) together with the applicable Prepayment Charge. Notwithstanding the foregoing, Agent and Lender agree to waive the Prepayment Charge if Agent and Lender (in its sole and absolute discretion) agree in writing to refinance and redocument this Agreement prior to the Term Loan Maturity Date and if in connection with such refinancing and redocumentation, Agent and Lender expressly agree in writing to waive the Prepayment Charge. 

2.5End of Term Charge.  On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) in full, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay Lender a charge equal to four and one half of one percent (4.5%) of the greater of (x) Twenty Million Dollars ($20,000,000), or (y) the aggregate original principal amount of all Term Loan Advances extended by Lender (the “End of Term Charge”). Notwithstanding the required payment date of such charge, it shall be deemed earned by Lender as of the Closing Date.

2.6Notes.  If so requested by Lender by written notice to Borrower, then Borrower shall execute and deliver to Lender (and/or, if applicable and if so specified in such notice, to any Person who is an assignee of Lender pursuant to Section 11.13) (promptly after Borrower’s receipt of such notice) a Note or Notes to evidence Lender’s Loans.

2.7Pro Rata Treatment.  Each payment (including prepayment) on account of any fee and any reduction of the Term Loan Advances shall be made pro rata according to the Term Commitments of the relevant Lender.

SECTION 3. SECURITY INTEREST

3.1As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Borrower grants to Agent a security interest in all of Borrower’s right, title, and interest in and to the following personal property whether now owned or hereafter acquired (collectively, the “Collateral”):  (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment Property; (g) Deposit Accounts; (h) Cash; (i) Goods; and all other tangible and intangible personal property (other than Intellectual Property) of Borrower whether now or 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower’s property in the possession or under the control of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing; provided, however, that the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property (the “Rights to Payment”).  Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Agent’s security interest in the Rights to Payment. 

3.2Notwithstanding the foregoing, the Collateral shall not include any Excluded Property.

3.3If this Agreement is terminated in accordance with its terms, Agent’s Lien in the Collateral shall continue until the Secured Obligations (other than inchoate indemnity obligations) are satisfied in full, and at such time Agent shall, at Borrower’s sole cost and expense, authorize Borrower to terminate its security interest in the Collateral and all rights therein shall automatically revert to Borrower.  Agent shall execute such documents and take such other steps as are reasonably necessary for Borrower to accomplish the foregoing, all at Borrower’s sole cost and expense.

SECTION 4. CONDITIONS PRECEDENT TO LOAN

The obligation of Lender to make the Term Loan Advances hereunder is subject to the satisfaction by Borrower of the following conditions:

4.1Initial Advance.  On or prior to the Closing Date, Borrower shall have delivered to Agent the following:

(a)executed copies of the Loan Documents (other than the Warrants, which shall be an original), Account Control Agreements, a legal opinion of Borrower’s counsel, and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance reasonably acceptable to Agent;

(b)certified copy of resolutions of Borrower’s Board evidencing approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrants and transactions evidenced thereby;

(c)certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower;

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

(d)a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect; 

(e)payment of the Due Diligence Fee, the Facility Charge and reimbursement of Agent’s and Lender’s current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; and 

(f)such other documents as Agent may reasonably request.

4.2All Advances.  On each Advance Date:

(a)Agent shall have received (i) an Advance Request for the relevant Advance as required by Section 2.1(b), each duly executed by Borrower’s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Agent may reasonably request.

(b)The representations and warranties set forth in this Agreement shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.

(c)Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing.

(d)Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.

4.3No Default.  As of the Closing Date and each Advance Date, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or would reasonably be expected to have a Material Adverse Effect has occurred and is continuing. 

SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER

Borrower represents and warrants that:

5.1Corporate Status.  Inc. is a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware.  LLC is a limited liability company duly organized, legally existing and in good standing under the laws of the State of Delaware.  Borrower is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified would reasonably be expected to have a Material Adverse Effect.  Borrower’s present name, former names (if any), locations, place of formation, tax identification number, 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Agent after the Closing Date.  

5.2Collateral.  Borrower owns the Collateral and the Intellectual Property, free of all Liens, except for Permitted Liens.  Borrower has the power and authority to grant to Agent a Lien in the Collateral as security for the Secured Obligations.  

5.3Consents.  Borrower’s execution, delivery and performance of the Note(s) (if any), this Agreement and all other Loan Documents, and Borrower’s execution of the Warrants, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate or Articles of Incorporation (as applicable), bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate any contract or agreement or require the consent or approval of any other Person which has not already been obtained.  The individual or individuals executing the Loan Documents and the Warrants are duly authorized to do so.

5.4Material Adverse Effect.  No event that has had or would reasonably be expected to have a Material Adverse Effect has occurred and is continuing. 

5.5Actions Before Governmental Authorities.  There are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened in writing against or affecting Borrower or its property, that is reasonably expected to result in a Material Adverse Effect. 

5.6Laws.  Borrower is not in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect.  Borrower is not in default in any manner under any provision of any agreement or instrument evidencing material Indebtedness, or any other material agreement to which it is a party or by which it is bound, where in each case such default would reasonably be expected to result in liability in excess of Two Hundred Fifty Thousand Dollars ($250,000).

5.7Information Correct and Current.  No information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained, or, when taken as a whole, contains or will contain any material misstatement of fact or, when taken together with all other such information or documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not materially misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Agent, whether prior to or after the Closing Date, shall be (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the most current of such projections provided to Borrower’s Board (it being understood that such projections are subject to significant uncertainties and contingencies, many of which are beyond 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

the control of Borrower, that no assurance is given that any particular projections will be realized, that actual results may differ).  

5.8Tax Matters.  Except as described on Schedule 5.8 and except those being contested in good faith with adequate reserves under GAAP, (a) Borrower has filed all material federal, state and local tax returns that it is required to file, (b) Borrower has duly paid or fully reserved for all taxes (other than de minimis amounts not exceeding Twenty Five Thousand Dollars ($25,000)) or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully reserved for any tax assessment received by Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings).

5.9Intellectual Property Claims.  To Borrower’s knowledge, Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property material to Borrower’s business.  To Borrower’s knowledge, except as described on Schedule 5.9, (i) each of the material Copyrights, Trademarks and Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) to the best of Borrower’s knowledge no claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party. Exhibit D is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder.  

5.10Intellectual Property.  To Borrower’s knowledge, except as described on Schedule 5.10, Borrower has all material rights with respect to Intellectual Property necessary or material in the operation or conduct of Borrower’s business as currently conducted by Borrower.  Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower’s business, to freely transfer, license or assign Intellectual Property necessary or material in the operation or conduct of Borrower’s business as currently conducted by Borrower, without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are material to Borrower’s business and used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products except customary covenants in inbound license agreements and equipment leases where Borrower is the licensee or lessee.  

5.11Borrower Products.  Except as described on Schedule 5.11, no Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened in writing litigation, proceeding (including any proceeding in 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any manner Borrower’s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future Intellectual Property related to the operation or conduct of the business of Borrower or Borrower Products.  Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower’s ownership in any Intellectual Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto nor, to Borrower’s knowledge, is there a reasonable basis for any such claim.  To Borrower’s knowledge, neither Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products infringes the issued patents, trademarks, and copyrights in any material respect.  

5.12Financial Accounts.  Exhibit E, as may be updated by Borrower in a written notice provided to Agent after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.

5.13Employee Loans.  Borrower has no outstanding loans to any employee, officer or director of Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of Borrower by a third party.

5.14Subsidiaries.  Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments.  Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary.

SECTION 6. INSURANCE; INDEMNIFICATION

6.1Coverage.  Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower’s line of business.  Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3.  Borrower must maintain a minimum of $1,000,000 of commercial general liability insurance for each occurrence.  Borrower has and agrees to maintain a minimum of $2,000,000 of directors’ and officers’ insurance for each occurrence and $5,000,000 in the aggregate.  So long as there are any Secured Obligations (other than inchoate indemnity obligations) outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles.  

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

6.2Certificates.  Borrower shall deliver to Agent certificates of insurance that evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2.  Borrower’s insurance certificate shall state Agent is an additional insured for commercial general liability, a loss payee for all risk property damage insurance, subject to the insurer’s approval, and a loss payee for property insurance and additional insured for liability insurance for any future liability insurance that Borrower may acquire from such insurer.  Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s loss payable endorsements for all risk property damage insurance.  All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Agent of cancellation (other than cancellation for non-payment of premiums, for which ten (10) days’ advance written notice shall be sufficient) or any other change adverse to Agent’s interests.  Any failure of Agent to scrutinize such insurance certificates for compliance is not a waiver of any of Agent’s rights, all of which are reserved. 

6.3Indemnity.  Borrower agrees to indemnify and hold Agent, Lender and their officers, directors, employees, agents, in-house attorneys, representatives and shareholders (each, an “Indemnified Person”) harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal) (collectively, “Liabilities”), that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent resulting solely from any Indemnified Person’s gross negligence or willful misconduct. Borrower agrees to pay, and to save Agent and Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by the net income of Agent or Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement.  

SECTION 7. COVENANTS OF BORROWER

Borrower agrees as follows: 

7.1Financial Reports.  Borrower shall furnish to Agent the financial statements and reports listed hereinafter (the “Financial Statements”):

(a)within 30 days after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated basis), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

to normal year end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements;  

(b)within 45 days after the end of the first three (3) calendar quarters in each fiscal year, unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated basis), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect,  certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year end adjustments; to the extent required by Form 10-Q, the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options;

(c)within 90 days after the end of each fiscal year, unqualified (other than a going concern qualification solely with respect to Borrower having less than twelve (12) months of cash for each fiscal year during the term of the Agreement) audited financial statements as of the end of such year (prepared on a consolidated basis), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent (it being understood that CohnReznick LLC and any nationally recognized big four (4) accounting firm is reasonably acceptable to Agent), accompanied by any management report from such accountants; 

(d)within 30 days after the end of each month, a Compliance Certificate in the form of Exhibit F;

(e)promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that Borrower has made available to holders of its capital stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;

(f)[Reserved]; and 

(g)within 60 days after the end of Borrower’s fiscal year, financial and business projections as approved by Borrower’s Board, as well as budgets, operating plans and other financial information reasonably requested by Agent.  

Borrower shall not make any change in its (a) accounting policies or reporting practices other than in accordance with GAAP and applicable regulations adopted by the SEC and the PCAOB (as applicable), or (b) unless Borrower shall have notified Agent in writing thirty (30) days in advance of such change, fiscal years or fiscal quarters. As of the Closing Date, the fiscal year of Borrower ends on December 31.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

The executed Compliance Certificate may be sent via facsimile to Agent at (650) 473-9194 or via e-mail to legal@herculestech.com.  All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com with a copy to legal@herculestech.com provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be sent via facsimile to Agent at: (866) 468-8916, attention Chief Credit Officer.

Notwithstanding the foregoing, documents required to be delivered pursuant to this Section 7.1 (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which (i) such financial statements and/or appropriate disclosures are publicly available as posted on the Electronic Data Gathering Analysis and Retrieval system (EDGAR) or any successor filing system of the SEC, or (ii) Borrower posts such documents, or provides a link thereto on the Borrower’s website on the Internet, provided, however, other than in connection with documents required to be delivered under Section 7.1(e).  Borrower shall promptly notify Agent and Lender in writing (which may be by electronic mail) of the posting of any such documents.  

7.2Management Rights.  Borrower shall permit any representative that Agent or Lender authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours; provided, however, that so long as no Event of Default has occurred and is continuing, such examinations shall be limited to no more often than twice per fiscal year.  In addition, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account and records.  In addition, Agent or Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower.  Such consultations shall not unreasonably interfere with Borrower’s business operations.  The parties intend that the rights granted Agent and Lender shall constitute “management rights” within the meaning of 29 C.F.R. Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Agent or Lender with respect to any business issues shall not be deemed to give Agent or Lender, nor be deemed an exercise by Agent or Lender of, control over Borrower’s management or policies. 

7.3Further Assurances.  Borrower shall from time to time execute, deliver and file, alone or with Agent, any financing statements, security agreements, collateral assignments, notices, control agreements, or other documents to perfect or give the highest priority to Agent’s Lien on the Collateral (subject to Permitted Liens that are permitted pursuant to the terms of this Agreement to have superior priority to Agent’s Lien under this Agreement).  Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Agent, and take all further action that may be necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby and thereby.  In addition, and for such purposes only, Borrower hereby authorizes Agent to execute and deliver on behalf of Borrower and to file such financing statements (including an indication that the financing statement covers “all assets or all personal property” of Borrower in accordance with Section 9-504 of the UCC), collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Agent’s name or in the name of Agent as agent and attorney-in-

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

fact for Borrower.  Borrower shall protect and defend Borrower’s title to the Collateral and Agent’s Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.   

7.4Indebtedness.  Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for (a) the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion, (b) purchase money Indebtedness pursuant to its then applicable payment schedule, (c) prepayment by any Subsidiary of (i) inter-company Indebtedness owed by such Subsidiary to any Borrower, or (ii) if such Subsidiary is not a Borrower, intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a Borrower or (d) as otherwise permitted hereunder or approved in writing by Agent.

7.5Collateral.  Borrower shall at all times keep the Collateral, the Intellectual Property  and all other property and assets used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process affecting the Collateral, the Intellectual Property,  such other property and assets, or any Liens thereon, provided however, that the Collateral and such other property and assets may be subject to Permitted Liens except that there shall be no Liens whatsoever on Intellectual Property.  Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property and assets free and clear from any legal process or Liens whatsoever (except for Permitted Liens, provided however, that there shall be no Liens whatsoever on Intellectual Property), and shall give Agent prompt written notice of any legal process affecting such Subsidiary’s assets. Borrower shall not agree with any Person other than Agent or Lender not to encumber its property other than with respect to (i) Excluded Property, (ii) any agreement evidencing Indebtedness secured by clause (vii) of the definition of Permitted Liens; and (iii) restrictions by reason of customary provisions restricting assignment, subletting or other transfers contained in leases, licenses and similar agreements entered into in the ordinary course of business (provided that such restrictions are limited to the property or assets secured by such Liens or the property or assets subject to such leases, licenses or similar agreements as the case may be).  

7.6Investments.  Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries so to do, other than Permitted Investments.

7.7Distributions.  Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than (i) pursuant to employee, director or consultant stock purchase or repurchase plans or other similar agreements so long as an Event of Default does not exist at the time of such repurchase and would not exist after giving effect to such repurchase, and provided that the aggregate amount of all such repurchases does not exceed $500,000, or (ii) conversion of any of its convertible securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

thereof; provided, however, in each case (i) and (ii), the repurchase or redemption price does not exceed the original consideration paid for such stock or equity interest, or (b) declare or pay any cash dividend or make a cash distribution on any class of stock or other equity interest, except that a Subsidiary may pay dividends or make distributions to Borrower or any other Subsidiary of Borrower, provided that such Subsidiary has entered into a Joinder Agreement and other documents as shall be reasonably requested by Agent, or (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of $100,000 in the aggregate or (d) waive, release or forgive any Indebtedness owed by any employees, officers or directors in excess of $100,000 in the aggregate. 

7.8Transfers.  Except for Permitted Transfers, Borrower shall not, and shall not allow any Subsidiary to, voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets.

7.9Mergers or Acquisitions.  Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of (a) a Subsidiary which is not a Borrower into another Subsidiary or into Borrower, (b) a Borrower into another Borrower, (c) any Person into a Borrower in a transaction in which the surviving entity is such Borrower or (d) any Person (other than a Borrower) into a Subsidiary in a transaction in which the surviving entity is such Subsidiary), or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person, except for Acquisitions permitted by Section 7.6.

7.10Taxes.  Borrower and its Subsidiaries shall pay when due all material taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Agent, Lender (other than taxes imposed on or measured by the Lender’s net income) or the Collateral or upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom.  Borrower shall file on or before the due date therefor all personal property tax returns in respect of the Collateral.  Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with GAAP.

7.11Corporate Changes.  Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days’ prior written notice to Agent.  Inc. shall not suffer a Change in Control. Neither Borrower nor any Qualified Subsidiary shall relocate its chief executive office or its principal place of business unless: (i) it has provided prior written notice to Agent; and (ii) such relocation shall be within the continental United States.  Neither Borrower nor any Qualified Subsidiary shall relocate any item of Collateral (other than (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up to $150,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has provided prompt written notice to Agent, (ii) such relocation is within the continental United States and, (iii) if such relocation is to a third party bailee, it has delivered a bailee agreement in form and substance reasonably acceptable to Agent.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

7.12Deposit Accounts.  Neither Borrower nor any Qualified Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property, except with respect to which Agent has an Account Control Agreement.   

7.13Subsidiaries. Borrower shall notify Agent of each Subsidiary formed subsequent to the Closing Date and, within 30 days of formation, shall cause any such Qualified Subsidiary to execute and deliver to Agent a Joinder Agreement.

7.14Notification of Event of Default.  Borrower shall notify Agent immediately upon becoming aware of the occurrence of any Event of Default.

7.15Small Business Administration. Agent and Lender have received a license from the U.S. Small Business Administration (“SBA”) to extend loans as a small business investment company (“SBIC”) pursuant to the Small Business Investment Act of 1958, as amended, and the associated regulations (collectively, the “SBIC Act”).  Portions of the loan to Borrower will be made under the SBA license and the SBIC Act.  Addendum 1 to this Agreement outlines various responsibilities of Agent, Lender and Borrower associated with an SBA loan, and such Addendum 1 is hereby incorporated in this Agreement

7.16Post-Closing Deliverables. Borrower shall deliver to Agent, within thirty (30) Business Days after the Closing Date, fully-executed Account Control Agreements by and among LLC, Agent, and Bank of America, covering each of LLC’s account no. xxxxxxxx9095 and account no. xxxxxxxx1066, and (b) within thirty (30) days after the Closing Date, endorsements to Borrower’s property and liability policies, which endorsements shall name Agent as lender loss payee and additional insured and provide that Agent shall receive prior notice of cancellation of such property and liability policies.

7.17Financial Covenant – Liquidity.  Borrower shall maintain at all times, in an account in the name of Borrower and subject to an Account Control Agreement, unrestricted (other than as a result of this covenant) cash in an amount equal to the lesser of (i) one (1) times the outstanding Secured Obligations of Borrower to Lender or (ii) one hundred percent (100%) of all cash of Borrower and its Subsidiaries (other than cash held in (a) Excluded Accounts or (b) other accounts in an aggregate amount not in excess of One Hundred Thousand Dollars ($100,000.00)).

SECTION 8. RIGHT TO INVEST

8.1At all times when any Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) shall be outstanding to Lender hereunder, Lender or its assignee or nominee shall have the right, in its discretion, to participate in any Subsequent Financing in an amount of up to Two Million Dollars ($2,000,000) on the same terms, conditions and pricing afforded to others participating in any such Subsequent Financing. 

SECTION 9. EVENTS OF DEFAULT

The occurrence of any one or more of the following events shall be an Event of Default:

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

9.1Payments.  Borrower fails to pay any amount due under this Agreement, the Note(s), or any of the other Loan Documents on the due date; provided, however, that an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational error of Lender or Borrower’s bank if Borrower had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower’s knowledge of such failure to pay; or 

9.2Covenants.  Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other Loan Documents or any other agreement among Borrower, Agent and Lender, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.14, and 7.15, 7.16, and 7.17), any other Loan Document or any other agreement among Borrower, Agent and Lender, such default continues for more than ten (10) days after the earlier of the date on which (i) Agent or Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.14, 7.15, 7.16 and 7.17, the occurrence of such default; or 

9.3Material Adverse Effect.  A circumstance has occurred that would reasonably be expected to have a Material Adverse Effect, provided that: (a) solely for the purposes of this Section 9.3, the occurrence of any of the following, in and of itself, shall not constitute a Material Adverse Effect: (i) adverse results or delays in any nonclinical or clinical trial, or (ii) the delay or limitation of approval of, or taking of any other regulatory action by, the United States Food and Drug Administration; and (b) if such circumstance is due to a change in or discontinuance of a strategic partnership or other collaboration or license agreement, Agent shall provide three (3) calendar days written notice to Inc. before exercising any right or remedy or causing an Event of Default to occur with respect to this Section 9.3, whereby during such time, Agent shall make itself available to discuss in good faith an proposed solution to such Material Adverse Effect); or

9.4Representations.  Any representation or warranty made by Borrower in any Loan Document shall have been false or misleading in any material respect when made or when deemed made; or 

9.5Insolvency.  Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) forty-five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or 

9.6Attachments; Judgments.  Any portion of Borrower’s assets is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money (not covered by independent third party insurance as to which liability has not been rejected by such insurance carrier), individually or in the aggregate, of at least $1,000,000, and such judgment remains unsatisfied, unvacated or unstayed for a period of fifteen (15) days after the entry thereof, or Borrower is enjoined or in any way prevented by court order from conducting any part of its business; or  

9.7Other Obligations.  The occurrence of any default (after giving effect to any grace or cure period, if any) under any agreement or obligation of Borrower involving any Indebtedness in excess of $1,000,000, which has resulted in a right by a third party, whether or not exercised, to accelerate the maturity of such Indebtedness.

SECTION 10. REMEDIES

10.1General.  Upon and during the continuance of any one or more Events of Default, (i) Agent may, at its option, accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.5, all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act), (ii) Agent may, at its option, sign and file in Borrower’s name any and all collateral assignments, notices, control agreements, security agreements and other documents it deems necessary or appropriate to perfect or protect the repayment of the Secured Obligations, and in furtherance thereof, Borrower hereby grants Agent an irrevocable power of attorney coupled with an interest, and (iii) Agent may notify any of Borrower’s account debtors to make payment directly to Agent, compromise the amount of any such account on Borrower’s behalf and endorse Agent’s name without recourse on any such payment for deposit directly to Agent’s account.  Agent may exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral.  All Agent’s rights and remedies shall be cumulative and not exclusive.

10.2Collection; Foreclosure.  Upon the occurrence and during the continuance of any Event of Default, Agent may, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

or following any commercially reasonable preparation or processing, in such order as Agent may elect.  Any such sale may be made either at public or private sale at its place of business or elsewhere.  Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower.  Agent may require Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient to Agent and Borrower.  The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in the following order of priorities: 

First, to Agent and Lender in an amount sufficient to pay in full Agent’s and Lender’s reasonable costs and professionals’ and advisors’ fees and expenses as described in Section 11.11;

Second, to Lender in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Agent may choose in its sole discretion; and

Finally, after the full and final payment in Cash of all of the Secured Obligations (other than inchoate obligations), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.

Agent shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.

10.3No Waiver.  Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.  

10.4Cumulative Remedies.  The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative.  The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Agent.

SECTION 11. MISCELLANEOUS

11.1Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

11.2Notice.  Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

facsimile, electronic mail or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows: 

		
	
If to Agent:
	
HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

	
 
	
Legal Department

	
 
	
Attention:  Chief Legal Officer and Mr. Bryan Jadot

	
 
	
400 Hamilton Avenue, Suite 310

	
 
	
Palo Alto, CA  94301

	
 
	
Email: legal@herculestech.com

	
 
	
Facsimile:  650-473-9194

	
 
	
Telephone:  650-289-3060

	
and to:
	
Ben Bang

	
 
	
Email: bbang@herculestech.com

	
If to Lender:
	
HERCULES TECHNOLOGY II, L.P.

	
 
	
HERCULES TECHNOLOGY III, L.P.

	
 
	
Legal Department

	
 
	
Attention:  Chief Legal Officer and Mr. Bryan Jadot

	
 
	
400 Hamilton Avenue, Suite 310

	
 
	
Palo Alto, CA  94301

	
 
	
Email: legal@herculestech.com

	
 
	
Facsimile:  650-473-9194

	
 
	
Telephone:  650-289-3060

	
If to Borrower
	
Paratek Pharmaceuticals, Inc.

	
 
	
Attention: Chief Financial Officer

	
 
	
75 Park Place, 4th Floor

	
 
	
Boston, Massachusetts 02111

	
 
	
Facsimile:  617-275-0039

	
 
	
Telephone: 617-807-6600

	
with a copy to:
	
Paratek Pharmaceuticals, Inc.

	
 
	
Attention: General Counsel

	
 
	
75 Park Place, 4th Floor

	
 
	
Boston, Massachusetts 02111

or to such other address as each party may designate for itself by like notice.

11.3Entire Agreement; Amendments.  

(a)This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Agent’s revised proposal letter dated August 14, 2015).  

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

(b)Neither this Agreement, any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified except in accordance with the provisions of this Section 11.3(b).  The Required Lenders and Borrower party to the relevant Loan Document may, or, with the written consent of the Required Lenders, Agent and Borrower party to the relevant Loan Document may, from time to time, (i) enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of Lenders or of Borrower hereunder or thereunder or (ii) waive, on such terms and conditions as the Required Lenders or Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or modification shall (A) forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of any amortization payment in respect of any Term Loan Advance, reduce the stated rate of any interest or fee payable hereunder, or extend the scheduled date of any payment thereof, in each case without the written consent of each Lender directly affected thereby; (B) eliminate or reduce the voting rights of any Lender under this Section 11.3(b) without the written consent of such Lender; (C) reduce any percentage specified in the definition of Required Lenders, consent to the assignment or transfer by Borrower of any of its rights and obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral or release a Borrower from its obligations under the Loan Documents, in each case without the written consent of all Lenders; or (D) amend, modify or waive any provision of Section 11.17 without the written consent of Agent.  Any such waiver and any such amendment, supplement or modification shall apply equally to each Lender and shall be binding upon Borrower, Lender, Agent and all future holders of the Loans. 

(c)Upon any sale, transfer or disposition by Borrower or any Subsidiary of any of the Clinical Assets or royalties (or rights therein or related thereto), rights to payment under royalties, licenses and the proceeds thereof in connection with a Royalty Backed Indebtedness Transaction, any security interest in such Collateral shall be automatically released and Agent and at Borrower’s sole expense, the Lenders shall execute such amendments, consents, releases (including UCC-3 financing statement amendments) and other similar documents as may be reasonably necessary under the Loan Documents to give effect to and otherwise permit such transaction.

11.4No Strict Construction.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

11.5No Waiver.  The powers conferred upon Agent and Lender by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or Lender to exercise any such powers.  No omission or delay by Agent or Lender at any time to enforce any right or remedy reserved to it, 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Agent or Lender is entitled, nor shall it in any way affect the right of Agent or Lender to enforce such provisions thereafter. 

11.6Survival.  All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Agent and Lender and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement.

11.7Successors and Assigns.  The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any).  Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents without Agent’s express prior written consent, and any such attempted assignment shall be void and of no effect.  Agent and Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights shall inure to the benefit of Agent’s and Lender’s successors and assigns; provided that as long as no Event of Default has occurred and is continuing, neither Agent nor any Lender may assign, transfer or endorse its rights hereunder or under the Loan Documents to any party that is a direct competitor of Borrower (as reasonably determined by Agent), it being acknowledged that in all cases, any transfer to an Affiliate of any Lender or Agent shall be allowed.

11.8Governing Law.  This Agreement and the other Loan Documents have been negotiated and delivered to Agent and Lender in the State of California, and shall have been accepted by Agent and Lender in the State of California.  Payment to Agent and Lender by Borrower of the Secured Obligations is due in the State of California.  This Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

11.9Consent to Jurisdiction and Venue.  All judicial proceedings (to the extent that the reference requirement of Section 11.10 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court located in the State of California.  By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or the other Loan Documents.  Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2.  Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

11.10Mutual Waiver of Jury Trial / Judicial Reference.  

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

(a)Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws.  EACH OF BORROWER, AGENT AND LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST AGENT, LENDER OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, LENDER OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER.  This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower and Lender; Claims that arise out of or are in any way connected to the relationship among Borrower, Agent and Lender; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.   

(b)If the waiver of jury trial set forth in Section 11.10(a) is ineffective or unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of Santa Clara County, California.  Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding.    

(c)In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.9, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.

11.11Professional Fees.  Borrower promises to pay Agent’s and Lender’s fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable attorneys fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’ and other professionals’ fees and expenses incurred by Agent and Lender after the Closing Date in connection with or related to:  (a) the Loan; (b) the administration, collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Agent or Lender in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

11.12Confidentiality.  Agent and Lender acknowledge that certain items of Collateral and information provided to Agent and Lender by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential (the “Confidential Information”).  Accordingly, Agent and Lender agree that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting  Agent’s security interest in the Collateral shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Agent and Lender may disclose any such information:  (a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its Affiliates if Agent or Lender in their sole discretion determines that any such party should have access to such information in connection with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Agent or Lender; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Agent’s or Lender’s counsel; (e) to comply with any legal requirement or law applicable to Agent or Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including Agent’s sale, lease, or other disposition of Collateral after default; (g) to any participant or assignee of Agent or Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or the other Loan Documents.  

11.13Assignment of Rights.  Borrower acknowledges and understands that Agent or Lender may, subject to Section 11.7, sell and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity (an “Assignee”).  After such assignment the term “Agent” or “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and Lender hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Agent and Lender shall retain all rights, powers and remedies hereby given.  No such assignment by Agent or Lender shall relieve Borrower of any of its obligations hereunder.  Lender agrees that in the event of any transfer by it of the Note(s)(if any), it will endorse thereon a notation as to the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.

11.14Revival of Secured Obligations.  This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

from Agent or Lender.  The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral had not been made.  In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Agent or Lender in Cash. 

11.15Counterparts.  This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.

11.16No Third Party Beneficiaries.  No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, Lender and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely among Agent, Lender and Borrower. 

11.17Agency.

(a)Lender hereby irrevocably appoints Hercules Technology Growth Capital, Inc. to act on its behalf as Agent hereunder and under the other Loan Documents and authorizes Agent to take such actions on its behalf and to exercise such powers as are delegated to Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.

(b)Lender agrees to indemnify Agent in its capacity as such (to the extent not reimbursed by Borrower and without limiting the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding Term Loan Commitments) in effect on the date on which indemnification is sought under this Section 11.17, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time be imposed on, incurred by or asserted against Agent in any way relating to or arising out of, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by Agent under or in connection with any of the foregoing; The agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder.

(c)Agent in Its Individual Capacity.  The Person serving as Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not Agent and the term “Lender” shall, unless 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as Agent hereunder in its individual capacity.  

(d)Exculpatory Provisions.  Agent shall have no duties or obligations except those expressly set forth herein and in the other Loan Documents.  Without limiting the generality of the foregoing, Agent shall not:

(i)be subject to any fiduciary or other implied duties, regardless of whether any default or any Event of Default has occurred and is continuing;

(ii)have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that Agent is required to exercise as directed in writing by Lender, provided that Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose Agent to liability or that is contrary to any Loan Document or applicable law; and

(iii)except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and Agent shall not be liable for the failure to disclose, any information relating to Borrower or any of its Affiliates that is communicated to or obtained by any Person serving as Agent or any of its Affiliates in any capacity.

(e)Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of Lender or as Agent shall believe in good faith shall be necessary, under the circumstances or (ii) in the absence of its own gross negligence or willful misconduct.

(f)Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to Agent. 

(g)Reliance by Agent.  Agent may rely, and shall be fully protected in acting, or refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties.  In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of the statements and the 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and conforming to the requirements of the Loan Agreement or any of the other Loan Documents.  Agent may consult with counsel, and any opinion or legal advice of such counsel shall be full and complete authorization and protection in respect of any action taken, not taken or suffered by Agent hereunder or under any Loan Documents in accordance therewith.  Agent shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction.  Agent shall not be under any obligation to exercise any of the rights or powers granted to Agent by this Agreement, the Loan Agreement and the other Loan Documents at the request or direction of Lenders unless Agent shall have been provided by Lender with adequate security and indemnity against the costs, expenses and liabilities that may be incurred by it in compliance with such request or direction. 

11.18Publicity.  None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties’ prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a) the other party's name (including a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties’ web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the " Publicity Materials"); (b) the names of officers of such other parties in the Publicity Materials; and (c) such other parties’ name, trademarks, servicemarks in any news or press release concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i) to the extent necessary to comply with the requests of any regulators, legal requirements or laws applicable to such party, pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other party hereto to the extent reasonably practicable) and (ii) to comply with Section 11.12.   

11.19Borrower Liability.  Either Borrower may, acting singly, request Advances hereunder.  Each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Advances hereunder.  Each Borrower hereunder shall be jointly and severally obligated to repay all Advances made hereunder, regardless of which Borrower actually receives said Advance, as if each Borrower hereunder directly received all Advances.  Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, including, without limitation, the benefit of California Civil Code Section 2815 permitting revocation as to future transactions and the benefit of California Civil Code Sections 1432, 2809, 2810, 2819, 2839, 2845, 2847, 2848, 2849, 2850, and 2899 and 3433, and (b) any right to require Lender to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy.  Lender may exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower’s liability.  Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Lender under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Secured Obligations, for any payment made by Borrower with respect to the Secured Obligations in connection with this Agreement or otherwise and all rights that it might have to 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

benefit from, or to participate in, any security for the Secured Obligations as a result of any payment made by Borrower with respect to the Secured Obligations in connection with this Agreement or otherwise.  Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void.  If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for Lender and such payment shall be promptly delivered to Lender for application to the Secured Obligations, whether matured or unmatured. 

(SIGNATURES TO FOLLOW)

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

IN WITNESS WHEREOF, Borrower, Agent and Lender have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.

		
	
BORROWER:

	
PARATEK PHARMACEUTICALS, INC.

	
Signature:
	
/s/ Douglas W. Pagán

	
Print Name:
	
Douglas W. Pagán

	
Title:
	
Chief Financial Officer

	
 
	
 

	
PARATEK PHARMA, LLC

	
Signature:
	
/s/ Douglas W. Pagán

	
Print Name:
	
Douglas W. Pagán

	
Title:
	
Chief Financial Officer

	
 
	
 

Accepted in Palo Alto, California:

		
	
AGENT:

	
HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

	
Signature:
	
/s/ Ben Bang

	
Print Name:
	
Ben Bang

	
Title:
	
Associate General Counsel

	
 
	
 

	
LENDER:

	
HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership

	
By:
	
Hercules Technology SBIC Management, LLC, its General Partner

	
By:
	
Hercules Technology Growth Capital, Inc., its Manager

	
Signature:
	
/s/ Ben Bang

	
Print Name:
	
Ben Bang

	
Title:
	
Associate General Counsel

 

 

(Signature Page to Loan and Security Agreement)

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

		
	
HERCULES TECHNOLOGY III, L.P., a Delaware limited partnership

	
By:
	
Hercules Technology SBIC Management, LLC, its General Partner

	
By:
	
Hercules Technology Growth Capital, Inc., its Manager

	
Signature:
	
/s/ Ben Bang

	
Print Name:
	
Ben Bang

	
Title:
	
Associate General Counsel

 

 

 

 

 

 

(Signature page to Loan and Security Agreement)

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Table of Addenda, Exhibits and Schedules

 

		
	
Addendum 1: 
	
SBA Provisions

	
 
	
 

	
Exhibit A:
	
Advance Request 

	
 
	
Attachment to Advance Request

	
Exhibit B:
	
Promissory Note

	
Exhibit C:
	
Name, Locations, and Other Information for Borrower

	
Exhibit D:
	
Borrower’s Patents, Trademarks, Copyrights and Licenses

	
Exhibit E:
	
Borrower’s Deposit Accounts and Investment Accounts

	
Exhibit F:
	
Compliance Certificate

	
Exhibit G:
	
Joinder Agreement

	
Exhibit H:
	
ACH Debit Authorization Agreement

	
 
	
 

	
Schedule 1
	
Subsidiaries

	
Schedule 1.1
	
Commitments

	
 
	
 

	
Schedule 1A
	
Existing Permitted Indebtedness

	
Schedule 1B
	
Existing Permitted Investments

	
Schedule 1C
	
Existing Permitted Liens

	
Schedule 5.3
	
Consents, Etc.

	
Schedule 5.5
	
Actions Before Governmental Authorities

	
Schedule 5.8
	
Tax Matters

	
Schedule 5.9
	
Intellectual Property Claims

	
Schedule 5.10
	
Intellectual Property

	
Schedule 5.11
	
Borrower Products

	
Schedule 5.14
	
Capitalization

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

ADDENDUM 1 to LOAN AND SECURITY AGREEMENT

 

(a)Borrower’s Business.  For purposes of this Addendum 1, Borrower shall be deemed to include its “affiliates” as defined in Title 13 Code of Federal Regulations Section 121.103.  Borrower represents and warrants to Agent and Lender as of the Closing Date and covenants to Agent and Lender for a period of one year after the Closing Date with respect to subsections 2, 3, 4, 5, 6 and 7 below, as follows:

	
 
	
(i)
	
Size Status.  Borrower NAICS code is 325412 and Borrower does not have more than seven hundred fifty (750) employees;

	
 
	
(ii)
	
No Relender.  Borrower’s primary business activity does not involve, directly or indirectly, providing funds to others, purchasing debt obligations, factoring, or long-term leasing of equipment with no provision for maintenance or repair;

	
 
	
(iii)
	
No Passive Business.  Borrower is engaged in a regular and continuous business operation (excluding the mere receipt of payments such as dividends, rents, lease payments, or royalties).  Borrower’s employees are carrying on the majority of day to day operations.  Borrower will not pass through substantially all of the proceeds of the Loan to another entity;

	
 
	
(iv)
	
No Real Estate Business.  Borrower is not classified under Major Group 65 (Real Estate) or Industry No. 1531 (Operative Builders) of the SIC Manual.  The proceeds of the Loan will not be used to acquire or refinance real property unless Borrower (x) is acquiring an existing property and will use at least 51 percent of the usable square footage for its business purposes; (y) is building or renovating a building and will use at least 67 percent of the usable square footage for its business purposes; or (z) occupies the subject property and uses at least 67 percent of the usable square footage for its business purposes.

	
 
	
(v)
	
No Project Finance.  Borrower’s assets are not intended to be reduced or consumed, generally without replacement, as the life of its business progresses, and the nature of Borrower’s business does not require that a stream of cash payments be made to the business's financing sources, on a basis associated with the continuing sale of assets (e.g., real estate development projects and oil and gas wells).  The primary purpose of the Loan is not to fund production of a single item or defined limited number of items, generally over a defined production period, where such production will constitute the majority of the activities of Borrower (e.g., motion pictures and electric generating plants).

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

	
 
	
(vi)
	
No Farm Land Purchases.  Borrower will not use the proceeds of the Loan to acquire farm land which is or is intended to be used for agricultural or forestry purposes, such as the production of food, fiber, or wood, or is so taxed or zoned.

	
 
	
(vii)
	
No Foreign Investment.  The proceeds of the Loan will not be used substantially for a foreign operation.  At the time of the Loan, Borrower will not have more than 49 percent of its employees or tangible assets located outside the United States.  The representation in this subsection (vii) is made only as of the date hereof and shall not continue for one year as contemplated in the first sentence of this Section 1.

(b)Small Business Administration Documentation.  Agent and Lender acknowledge that Borrower completed, executed and delivered to Agent SBA Forms 480, 652 and 1031 (Parts A and B) together with a business plan showing Borrower’s financial projections (including balance sheets and income and cash flows statements) for the period described therein and a written statement (whether included in the purchase agreement or pursuant to a separate statement) from Agent regarding its intended use of proceeds from the sale of securities to Lender (the “Use of Proceeds Statement”).  Borrower represents and warrants to Agent and Lender that the information regarding Borrower and its affiliates set forth in the SBA Form 480, Form 652 and Form 1031 and the Use of Proceeds Statement delivered as of the Closing Date is accurate and complete.

(c)Inspection.  The following covenants contained in this Section (c) are intended to supplement and not to restrict the related provisions of the Loan Documents.  Subject to the preceding sentence, Borrower will permit, for so long as Lender holds any debt or equity securities of Borrower, Agent, Lender or their representative, at Agent’s or Lender’ expense, and examiners of the SBA to visit and inspect the properties and assets of Borrower, to examine its books of account and records, and to discuss Borrower’s affairs, finances and accounts with Borrower’s officers, senior management and accountants, all at such reasonable times as may be requested by Agent or Lender or the SBA.

(d)Annual Assessment.  Promptly after the end of each calendar year (but in any event prior to February 28 of each year) and at such other times as may be reasonably requested by Agent or Lender, Borrower will deliver to Agent a written assessment of the economic impact of Lender’s investment in Borrower, specifying the full-time equivalent jobs created or retained in connection with the investment, the impact of the investment on the businesses of Borrower in terms of expanded revenue and taxes, other economic benefits resulting from the investment (such as technology development or commercialization, minority business development, or expansion of exports) and such other information as may be required regarding Borrower in connection with the filing of Lender’s SBA Form 468.   Lender will assist Borrower with preparing such assessment.  In addition to any other rights granted hereunder, Borrower will grant Agent and Lender and the SBA access to Borrower’s books and records for the purpose of verifying the use of such proceeds.  Borrower also will furnish or cause to be furnished to Agent and Lender such other information regarding the business, affairs and condition of Borrower as Agent or Lender may from time to time reasonably request. 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

(e)Use of Proceeds.  Borrower will use the proceeds from the Loan only for purposes set forth in this Addendum 1.  Borrower will deliver to Agent from time to time promptly following Agent’s request, a written report, certified as correct by Borrower's Chief Financial Officer, verifying the purposes and amounts for which proceeds from the Loan have been disbursed.  Borrower will supply to Agent such additional information and documents as Agent reasonably requests with respect to its use of proceeds and will permit Agent and Lender and the SBA to have access to any and all Borrower records and information and personnel as Agent deems necessary to verify how such proceeds have been or are being used, and to assure that the proceeds have been used for the purposes specified in this Addendum 1.

(f)Activities and Proceeds.  Neither Borrower nor any of its affiliates (if any) will engage in any activities or use directly or indirectly the proceeds from the Loan for any purpose for which a small business investment company is prohibited from providing funds by the SBIC Act, including 13 C.F.R. §107.720.  Without obtaining the prior written approval of Agent, Borrower will not change within 1 year of the date hereof, Borrower’s current business activity to a business activity which a licensee under the SBIC Act is prohibited from providing funds by the SBIC Act.

(g)Redemption Provisions.  Notwithstanding any provision to the contrary contained in the Certificate of Incorporation of Borrower, as amended from time to time (the “Charter”), if, pursuant to the redemption provisions contained in the Charter, Lender is entitled to a redemption of its Warrant, such redemption (in the case of Lender) will be at a price equal to the redemption price set forth in the Charter (the “Existing Redemption Price”).  If, however, Lender delivers written notice to Borrower that the then current regulations promulgated under the SBIC Act prohibit payment of the Existing Redemption Price in the case of an SBIC (or, if applied, the Existing Redemption Price would cause the Series C Preferred Stock to lose its classification as an “equity security” and Lender has determined that such classification is unadvisable), the amount Lender will be entitled to receive shall be the greater of (i) fair market value of the securities being redeemed taking into account the rights and preferences of such securities plus any costs and expenses of the Lender incurred in making or maintaining the Warrant, and (ii) the Existing Redemption Price where the amount of accrued but unpaid dividends payable to the Lender is limited to Borrower's earnings plus any costs and expenses of the Lender incurred in making or maintaining the Warrant; provided, however, the amount calculated in subsections (i) or (ii) above shall not exceed the Existing Redemption Price.

(h)Compliance and Resolution.   Borrower agrees that a failure to comply with Borrower’s obligations under this Addendum, or any other set of facts or circumstances where it has been asserted by any governmental regulatory agency (or Agent or Lender believes that there is a substantial risk of such assertion) that Agent, Lender and their affiliates are not entitled to hold, or exercise any significant right with respect to, any securities issued to Lender by Borrower, will constitute a breach of the obligations of Borrower under the financing agreements among Borrower, Agent and Lender.  In the event of (i) a failure to comply with Borrower’s obligations under this Addendum; or (ii) an assertion by any governmental regulatory agency (or Agent or Lender believes that there is a substantial risk of such assertion) of a failure to comply with Borrower’s obligations under this Addendum, then (i) Agent, Lender and Borrower will meet and resolve any such issue in good faith to the satisfaction of Borrower, Agent, Lender, and any governmental regulatory agency, and (ii) upon request of Lender or Agent, Borrower will 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

cooperate and assist with any assignment of the financing agreements among Hercules Technology II, L.P., Hercules Technology III, L.P., and Hercules Technology Growth Capital, Inc. 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT A
ADVANCE REQUEST

			
	
To: 
	
Agent:
	
Date: __________, 201_

	
 
	
Hercules Technology Growth Capital, Inc. (the “Agent”)
	
 

	
 
	
400 Hamilton Avenue, Suite 310
	
 

	
 
	
Palo Alto, CA 94301
	
 

	
 
	
Facsimile:  650-473-9194
	
 

	
 
	
Attn:
	
 

Paratek Pharmaceuticals, Inc. and Paratek Pharma, LLC (jointly and severally, individually and collectively, the “Borrower”) hereby requests from Hercules Technology Growth Capital, Inc. (“Lender”) an Advance in the amount of _____________________ Dollars ($________________) on ______________, _____ (the “Advance Date”) pursuant to the Loan and Security Agreement among Borrower, Agent and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement.

Please:

 

						
	
(a)
	
 
	
Issue a check payable to Borrower
	
 
	
 

	
 
	
 
	
or
	
 
	
 

	
(b)
	
 
	
Wire Funds to Borrower’s account
	
 
	
 

	
 
	
 
	
Bank:
	
 
	
 
	
 

	
 
	
 
	
Address:
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
ABA Number:
	
 
	
 
	
 

	
 
	
 
	
Account Number:
	
 
	
 
	
 

	
 
	
 
	
Account Name:
	
 
	
 
	
 

	
 
	
 
	
Contact Person:
	
 
	
 
	
 

	
 
	
 
	
Phone Number
	
 
	
 
	
 

	
 
	
 
	
To Verify Wire Info:
	
 
	
 
	
 

	
 
	
 
	
Email address:
	
 
	
 
	
 

 

Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied and shall be satisfied upon the making of such Advance, including but not limited to:  (i) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; (ii) that the representations and warranties set forth in the Agreement and in the Warrants are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (iii) that Borrower is in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iv) that as of the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents.  Borrower understands and 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

acknowledges that Agent has the right to review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance.

Borrower hereby represents that Borrower’s corporate status and locations have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request.

Borrower agrees to notify Agent promptly before the funding of the Loan if any of the matters which  have been represented above shall not be true and correct on the Borrowing Date and if Agent has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date.

Executed as of ____________________, 201_.

 

		
	
BORROWER:

	
 

	
PARATEK PHARMACEUTICALS, INC.

	
SIGNATURE:
	
 

	
TITLE:
	
 

	
PRINT NAME:
	
 

	
 
	
 

	
PARATEK PHARMA, LLC

	
SIGNATURE:
	
 

	
TITLE:
	
 

	
PRINT NAME:
	
 

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

ATTACHMENT TO ADVANCE REQUEST

Dated: _______________________

Borrower hereby represents and warrants to Agent that Borrower’s current name and organizational status is as follows:

	
 
	
Name:
	
[                                      ]

 

	
 
	
Type of organization:
	
[                                      ]

 

	
 
	
State of organization:
	
[                                      ]

 

	
 
	
Organization file number:
	
[                                      ]

 

Borrower hereby represents and warrants to Agent that the street addresses, cities, states and postal codes of its current locations are as follows:

 

 

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT B
PROMISSORY NOTE

		
	
$[  ],000,000
	
Advance Date:  ___ __, 20[  ]

	
 
	
Maturity Date:  ___ __, 20[  ]

FOR VALUE RECEIVED, Paratek Pharmaceuticals, Inc., a Delaware corporation, and Paratek Pharma, LLC, a Delaware limited liability company, for themselves and each of their Qualified Subsidiaries (individually and collectively, jointly and severally, the “Borrower”) hereby promises to pay to the order of Hercules Technology Growth Capital, Inc., a Maryland corporation or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of [  ] Million Dollars ($[  ],000,000) or such other principal amount as Lender has advanced to Borrower, together with interest at a rate as set forth in Section 2.1(c) of the Loan Agreement based upon a year consisting of 360 days, with interest computed daily based on the actual number of days in each month.

This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated September 30, 2015, by and among Borrower, Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Agent”) and the several banks and other financial institutions or entities from time to time party thereto as lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof.  All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein.  An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note.

Borrower waives presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law.   Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense.  This Promissory Note has been negotiated and delivered to Lender and is payable in the State of California.  This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that would cause the application of the laws of any other jurisdiction.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

BORROWER FOR ITSELF:

 

	
	
PARATEK PHARMACEUTICALS, INC.

	
By:

	
Title:

	
 

	
PARATEK PHARMA, LLC

	
By:

	
Title:

 

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT C:

 

NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER

 

 

I.  Paratek Pharmaceuticals, Inc.

1.  Inc. represents and warrants to Agent that Inc.’s current name and organizational status as of the Closing Date is as follows:

		
	
Name:
	
Paratek Pharmaceuticals, Inc. 

	
Type of organization:
	
Corporation

	
State of organization:
	
Delaware

	
Organization file number:
	
3362025

2.  Inc. represents and warrants to Agent that for five (5) years prior to the Closing Date, Inc. did not do business under any other name or organization or form except the following:

		
	
Name:
	
Transcept Pharmaceuticals, Inc.

	
Used during dates of:
	
Prior to Oct 2014

	
Type of Organization:
	
Corporation

	
State of organization:
	
Delaware 

	
Organization file Number: 3362025

	
Inc.’s fiscal year ends on December 31. 

	
Inc.’s federal employer tax identification number is: 33-0960223

3.  Inc. represents and warrants to Agent that its chief executive office is located at 75 Park Plaza, 4th Floor, Boston, MA 02116.

 

 

II.  Paratek Pharma, LLC

 

2.  LLC represents and warrants to Agent that LLC’s current name and organizational status as of the Closing Date is as follows:

			
	
Name:
	
Paratek Pharma, LLC
	
 

	
Type of organization:
	
Limited Liability Company
	
 

	
State of organization:
	
Delaware
	
 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
Organization file number:
	
5560633
	
 

2.  LLC represents and warrants to Agent that for five (5) years prior to the Closing Date, LLC did not do business under any other name or organization or form except the following:

		
	
Name:
	
Tigris Acquisition Sub, LLC

	
Used during dates of:
	
June 2014 – October 2014

	
Type of Organization:
	
Limited Liability Company

	
State of organization:
	
Delaware

	
Organization file Number:  5560633

	
LLC’s fiscal year ends on December 31

	
LLC’s federal employer tax identification number is:  47-2035918  

       3.  LLC represents and warrants to Agent that its chief executive office is located at 75 Park Plaza, 4th Floor, Boston, MA 02116.

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT D:

 

BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES

 

 

 

 

[See attached]

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

 

	
	
EXHIBIT D

	
PARATEK PHARMACEUTICALS, INC. PATENT PORTFOLIO

	
CONFIDENTIAL

 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
McCarter Ref.
	
Paratek Ref.
	
Country
	
Appln. No.
	
Filing Date
	
Patent No.
	
Issue Date
	
Title
	
Status

	
124418-01803
	
PKZ-018
	
US
	
09/660598
	
09/13/2000 
	
6617318B1
	
09/09/2003 
	
METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES
	
Granted

	
124418-01804
	
PKZ-0018CPDV
	
US
	
10/616531
	
07/09/2003 
	
7067681B2
	
06/27/2006 
	
METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES
	
Granted

	
124418-01808
	
PKZ-018CPCN2
	
US
	
11/004559
	
12/03/2004 
	
8106225
	
01/31/2012 
	
METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES
	
Granted

	
124418-02101
	
PKZ-021CPRCE
	
US
	
09/768189
	
01/23/2001 
	
6833365B2
	
12/21/2004 
	
TETRACYCLINE COMPOUNDS FOR TREATMENT OF CRYPTOSPORIDIUM PARVUM RELATED DISORDERS
	
Granted

	
124418-02501
	
PAZ-025CP
	
US
	
09/823884
	
03/30/2001 
	
6818634 B2
	
11/16/2004 
	
7- AND 9-CARBAMATE, UREA, THIOUREA, THICARBAMATE, AND HETEROARYL-AMINO SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-03507
	
PKZ-035CN4
	
US
	
12/476053
	
06/01/2009 
	
8012711
	
09/06/2011 
	
METHODS OF SCREENING FOR COMPOUNDS THAT REDUCE MICROBIAL RESISTANCE TO FLUOROQUINOLONES
	
Granted

	
124418-05406
	
PAZ-054CP2RCE
	
US
	
10/700661
	
11/03/2003 
	
7405235 B2
	
07/29/2008 
	
TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF
	
Granted

	
124418-05601
	
PAZ-056
	
US
	
09/852908
	
05/10/2001 
	
6642270B2
	
11/04/2003 
	
7-SUBSTITUTED FUSED RING TETRACYCLINE COMPOUNDS
	
Granted

	
124418-05606
	
PAZ-056CPCN4
	
US
	
13/031075
	
02/18/2011 
	
8288570
	
10/16/2012 
	
7- SUBSTITUTED FUSED RING TETRACYCLINE COMPOUNDS
	
Granted

	
124418-05639
	
PAZ-056HKDV2
	
HK
	
11110200.2
	
09/27/2011 
	
 
	
 
	
7 SUBSTITUTED FUSED RING TETRACYCLINE COMPOUNDS
	
Published

	
124418-05683
	
PAZ-056EPDV2
	
EP
	
10181635.3
	
05/10/2001 
	
 
	
 
	
7 SUBSTITUTED FUSED RING TETRACYCLINE COMPOUNDS
	
Published

	
124418-05701
	
PKZ-057CN2
	
US
	
11/706111
	
02/13/2007 
	
7521437
	
04/21/2009 
	
7-PHENYL-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-05703
	
PAZ-057CN4
	
US
	
12/967906
	
12/14/2010 
	
8168810
	
05/01/2012 
	
7-PHENYL-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-05801
	
PAZ-058CN4
	
US
	
12/356907
	
01/21/2009 
	
8012951
	
09/06/2011 
	
7-N-SUBSTITUTED PHENYL TETRACYCLINE COMPOUNDS
	
Granted

	
124418-05802
	
PAZ-058CN5
	
US
	
13/173968
	
06/30/2011 
	
8293931
	
10/23/2012 
	
7-N-SUBSTITUTED PHENYL TETRACYCLINE COMPOUNDS
	
Granted

	
124418-06401
	
PKZ-064
	
US
	
09/894805
	
06/29/2001 
	
6624168B2
	
09/23/2003 
	
7, 8 AND 9-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-06403
	
PKZ-064CN3
	
US
	
11/454221
	
06/16/2006 
	
7361674 B2
	
04/22/2008 
	
7, 8 AND 9-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-06406
	
PKZ-064CPDV
	
US
	
13/012590
	
01/24/2011 
	
8252777
	
08/28/2012 
	
7, 8 AND 9-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-06501
	
PKZ-065CPDV
	
US
	
12/635423
	
12/10/2009 
	
8119622
	
02/21/2012 
	
7- PHENYL-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-06902
	
PAZ-069CPCN
	
US
	
10/285975
	
11/01/2002 
	
6849615B2
	
02/01/2005 
	
13-SUBSTITUTED METHACYCLINE COMPOUNDS
	
Granted

	
124418-08003
	
PAZ-080CP
	
US
	
09/895812
	
06/29/2001 
	
6818635 B2
	
11/16/2004 
	
7-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-08005
	
PAZ-0080CPCN2
	
US
	
12/481368
	
06/09/2009 
	
8492365 B2
	
07/23/2013 
	
7-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-08101
	
PAZ-081CP
	
US
	
09/895797
	
06/29/2001 
	
6683068B2
	
01/27/2004 
	
7,9-SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-08181
	
PAZ-081CPMX
	
MX
	
PA/a/2003/008165
	
09/10/2003 
	
237137
	
05/24/2006 
	
7,9-SUBSTITUTED TETRACYLINE COMPOUNDS
	
Granted

	
124418-08201
	
PAZ-082CP
	
US
	
09/895857
	
06/29/2001 
	
6846939B2
	
01/25/2005 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08202
	
PAZ-082CPDV
	
US
	
10/839023
	
05/04/2004 
	
8048867
	
11/01/2011 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08203
	
PAZ-082CPCN2
	
US
	
12/351405
	
01/09/2009 
	
8258120
	
09/04/2012 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08207
	
PAZ-0082CPCN4
	
US
	
13/547870
	
07/12/2012 
	
9090541
	
07/28/2015 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08209
	
PAZ-0082CPCN5
	
US
	
14/732350
	
06/05/2015 
	
 
	
 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Pending

	
124418-08221
	
PAZ-082CPAL
	
AL
	
01965828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08222
	
PAZ-082CPAT
	
AT
	
01 96 5828.5
	
06/29/2001 
	
E336481
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08224
	
PAZ-082CPAU
	
AU
	
2001286388
	
06/29/2001 
	
2001286388
	
11/04/2005 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08225
	
PAZ-082CPBR
	
BR
	
PI0112269-0
	
06/29/2001 
	
 
	
 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Pending

	
124418-08226
	
PAZ-0082CPCA
	
CA
	
2415178
	
01/06/2003 
	
2415178
	
05/25/2010 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08227
	
PAZ-082CPBE
	
BE
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08228
	
PAZ-082CPCI
	
CN
	
01815087.X
	
06/29/2001 
	
ZL01815087.X
	
04/01/2009 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08229
	
PAZ-0082CPCH
	
CH
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-08232
	
PAZ-082CPDE
	
DE
	
01 96 5828.5
	
06/29/2001 
	
60122341.1-08
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08233
	
PAZ-082CPDK
	
DK
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08234
	
PAZ-082CPEA
	
EA
	
200300135
	
06/29/2001 
	
009175
	
12/28/2007 
	
SUBSTITUTED METHACYCLINE COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) AND METHOD FOR TREATING A TETRACYCLINE RESPONSIVE STATE IN A MAMMAL (VARIANTS)
	
Granted

	
124418-08235
	
PAZ-082CPEP
	
EP
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08237
	
PAZ-082CPES
	
ES
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08238
	
PAZ-082CPFI
	
FI
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08239
	
PAZ-082CPHKDV2
	
HK
	
11110199.5
	
09/27/2011 
	
 
	
 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Published

	
124418-08240
	
PAZ-082CPIN
	
IN
	
138/CHENP/2003
	
06/29/2001 
	
209561
	
09/05/2007 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08241
	
PAZ-082CPFR
	
FR
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08242
	
PAZ-082CPIL
	
IL
	
153639
	
06/29/2001 
	
153639
	
02/01/2011 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08243
	
PAZ-082CPJP
	
JP
	
2002-509074
	
06/29/2001 
	
4925549
	
02/17/2012 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08244
	
PAZ-082CPGB
	
GB
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08245
	
PAZ-082CPGR
	
GR
	
3059830
	
06/29/2001 
	
20060403922
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08246
	
PAZ-082CPKR
	
KR
	
10-2003-7000160
	
06/29/2001 
	
674047
	
 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08247
	
PAZ-082CPHR
	
HR
	
P20030091A
	
06/29/2001 
	
P20030091A
	
 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08248
	
PAZ-082CPMX
	
MX
	
PA/a/2003/000055
	
01/07/2003 
	
232833
	
12/13/2005 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08250
	
PAZ-0082CPHU
	
HU
	
P0301169
	
06/29/2001 
	
229577
	
01/10/2014 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08251
	
PAZ-082CPIE
	
IE
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08252
	
PAZ-082CPILDV
	
IL
	
177854
	
09/03/2006 
	
177854
	
05/29/2013 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08254
	
PAZ-082CPIT
	
IT
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08256
	
PAZ-082CPLT
	
LT
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-08257
	
PAZ-082CPLU
	
LU
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08258
	
PAZ-082CPLV
	
LV
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08259
	
PAZ-082CPMC
	
MC
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08260
	
PAZ-082CPMK
	
MK
	
MK/P2006/400
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08261
	
PAZ-082CPZA
	
ZA
	
2003/0749
	
06/29/2001 
	
2003/0749
	
08/31/2005 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08263
	
PAZ-082CPTW
	
TW
	
090116602
	
07/06/2001 
	
I299038
	
07/21/2008 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08264
	
PAZ-082CPNL
	
NL
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08265
	
PAZ0982CPPT
	
PT
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08266
	
PAZ-082CPRO
	
RO
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08267
	
PAZ-0082CPSE
	
SE
	
01 96 5828.5
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08268
	
PAZ-082CPSI
	
SI
	
P-200130646
	
06/29/2001 
	
1301467
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08269
	
PAZ-082CPTR
	
TR
	
01 96 5828.5
	
06/29/2001 
	
TR 2006 06401 T4
	
08/16/2006 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08280
	
PAZ-082CPCZDV
	
CZ
	
PV2009-877
	
06/29/2001 
	
303702
	
03/15/2013 
	
MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08282
	
PAZ-082CPEPDV2
	
EP
	
10182900.0
	
09/29/2010 
	
 
	
 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Published

	
124418-08283
	
PAZ-082CPINDV2
	
IN
	
2945/CHENP/2011
	
04/29/2011 
	
 
	
 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Published

	
124418-08284
	
PAZ-0082CPJPDV
	
JP
	
2008-157219
	
06/16/2008 
	
5037436
	
07/13/2012 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08285
	
PAZ-0082CPMXDV
	
MX
	
PA/a/2005/009949
	
09/19/2005 
	
267294
	
06/09/2009 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-08286
	
PAZ-0082CPMXCV2
	
MX
	
MX/a/2009/008670
	
08/13/2009 
	
309026
	
04/25/2013 
	
9-SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-11301
	
PAZ-113CPRCE
	
US
	
10/097457
	
03/14/2002 
	
6841546B2
	
01/11/2005 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS AS ANTIFUNGAL AGENTS
	
Granted

	
124418-11401
	
PAZ-114CP2RCE
	
US
	
10/692563
	
10/24/2003 
	
8088820
	
01/03/2012 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
	
Granted

	
124418-11435
	
PAZ-114CPEP
	
EP
	
02723955.7
	
04/24/2002 
	
1399414
	
01/13/2010 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-14201
	
PAZ-142CPCN
	
US
	
10/943571
	
09/16/2004 
	
7960366
	
06/14/2011 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS AS SYNERGISTIC ANTIFUNGAL AGENTS
	
Granted

	
124418-14202
	
PAZ-142CP
	
US
	
10/097634
	
03/14/2002 
	
7045507B2
	
05/16/2006 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS AS SYNERGISTIC ANTIFUNGAL AGENTS
	
Granted

	
124418-14707
	
PAZ-147CP2CN2
	
US
	
14/285105
	
05/22/2014 
	
 
	
 
	
TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Published

	
124418-14735
	
PAZ-147CPEP
	
EP
	
02748169.6
	
07/15/2002 
	
1408987
	
04/10/2013 
	
TETRACYLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Granted

	
124418-14743
	
PAZ-147CPJPDDV
	
JP
	
2009-187938
	
08/14/2009 
	
5182956
	
01/25/2013 
	
TETRACYLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Granted

	
124418-14782
	
PAZ-0147CPCH
	
CH
	
02748169.6
	
07/15/2002 
	
1408987
	
04/10/2013 
	
TETRACYLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Granted

	
124418-14783
	
PAZ-0147CPDE
	
DE
	
02748169.6
	
07/15/2002 
	
60244797.6
	
04/10/2013 
	
TETRACYLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Granted

	
124418-14784
	
PAZ-0147CPFR
	
FR
	
02748169.6
	
07/15/2002 
	
1408987
	
04/10/2013 
	
TETRACYLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Granted

	
124418-14785
	
PAZ-0147CPGB
	
GB
	
02748169.6
	
07/15/2002 
	
1408987
	
04/10/2013 
	
TETRACYLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Granted

	
124418-14786
	
PAZ-0147CPIE
	
IE
	
02748169.6
	
07/15/2002 
	
1408987
	
04/10/2013 
	
TETRACYLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
	
Granted

	
124418-16304
	
PAZ-163CPCN2
	
US
	
14/176923
	
02/10/2014 
	
 
	
 
	
4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS
	
Allowed

	
124418-16306
	
PAZ-163CP
	
US
	
10/337914
	
01/06/2003 
	
7056902B2
	
06/06/2006 
	
4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS
	
Granted

	
124418-16339
	
PAZ-163CPHKDV5
	
HK
	
11112270.3
	
11/14/2011 
	
 
	
 
	
4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS
	
Published

	
124418-16379
	
PAZ-163CPEPDV5
	
EP
	
10183340.8
	
02/04/2011 
	
2322501
	
08/05/2015 
	
4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS
	
Granted

	
124418-16382
	
PAZ-163CPJPDV2
	
JP
	
2014-260626
	
12/24/2014 
	
 
	
 
	
4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS
	
Published

	
124418-16383
	
PAZ-163CPEPDV6
	
EP
	
15176495.8
	
07/13/2015 
	
 
	
 
	
4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS
	
Pending

	
124418-17305
	
PAZ-173CPCN3
	
US
	
12/727114
	
03/18/2010 
	
8481513
	
07/09/2013 
	
3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-17306
	
PAZ-173CPCN4
	
US
	
13/936941
	
07/08/2013 
	
 
	
 
	
3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Pending

	
124418-17402
	
PAZ-174CN4
	
US
	
12/625282
	
11/24/2009 
	
8101591
	
01/24/2012 
	
9-AMINOACYL TETRACYCLINE COMPOUNDS AND METHODS OF USE THEREOF
	
Granted

	
124418-17503
	
PAZ-175CN5
	
US
	
13/038102
	
03/01/2011 
	
8304445
	
11/06/2012 
	
7-PYRAZOLYL TETRACYCLINE COMPOUNDS AND METHODS OF USE THEREOF
	
Granted

	
124418-17601
	
PAZ-176CN2
	
US
	
10/752378
	
01/05/2004 
	
7323492 B2
	
01/29/2008 
	
7-PYROLLYL 9-AMINOACYL TETRACYCLINE COMPOUNDS AND METHODS OF USE THEREOF (AS AMENDED)
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-17602
	
PAZ-176CN3
	
US
	
11/949392
	
12/03/2007 
	
8211937
	
07/03/2012 
	
7-PYROLLYL 9-AMINOACYL TETRACYCLINE COMPOUNDS AND METHODS OF USE THEREOF
	
Granted

	
124418-17804
	
PAZ-0178CPCN
	
US
	
10/737361
	
12/15/2003 
	
7326696 B2
	
02/05/2008 
	
AMINO-METHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-18101
	
PAZ-181CPCN
	
US
	
10/740961
	
12/18/2003 
	
7820641
	
10/26/2010 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-20502
	
PAZ-205CP
	
US
	
10/692764
	
10/24/2003 
	
8173624
	
05/08/2012 
	
METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA
	
Granted

	
124418-20505
	
PAZ-205CPCN3
	
US
	
14/790179
	
07/02/2015 
	
 
	
 
	
METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA
	
Pending

	
124418-22201
	
PAZ-222CNRCE
	
US
	
10/786881
	
02/24/2004 
	
7553828
	
06/30/2009 
	
9-AMINOMETHYL SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Granted

	
124418-22203
	
PAZ-222CN3
	
US
	
14/318031
	
06/27/2014 
	
 
	
 
	
9-AMINOMETHYL SUBSTITUTED MINOCYCLINE COMPOUNDS
	
Published

	
124418-22902
	
PAZ-0229CP
	
US
	
12/110627
	
04/28/2008 
	
 
	
 
	
METHODS FOR SYNTHESIZING AND PURIFYING AMINOALKYL COMPOUNDS
	
Published

	
124418-22904
	
PAZ-0229CPDVCN
	
US
	
14/041593
	
09/30/2013 
	
8946196
	
02/03/2015 
	
METHODS FOR SYNTHESIZING AND PURIFYING AMINOALKYL TETRACYCLINE COMPOUNDS
	
Granted

	
124418-23105
	
PAZ-0231CPCN
	
US
	
14/281357
	
05/19/2014 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Published

	
124418-23135
	
PAZ-0231CPEP
	
EP
	
04756012.3
	
06/25/2004 
	
1648859
	
02/27/2013 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-23140
	
PAZ-231CPINDV
	
IN
	
1640/CHENP/2009
	
03/23/2009 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Pending

	
124418-23146
	
PAZ-231CPKR
	
KR
	
10-2006-7000487
	
01/09/2006 
	
10-1228706
	
01/25/2013 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-26000
	
PAZ-0260CP
	
US
	
11/258622
	
10/25/2005 
	
8466132 B2
	
06/18/2013 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-26001
	
PAZ-260CPCN
	
US
	
13/918197
	
06/14/2013 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Published

	
124418-26085
	
PAZ-0260CPEPDV5
	
EP
	
10182880.4
	
09/29/2010 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Published

	
124418-26091
	
PAZ-260CPEPDV6
	
EP
	
15165987.7
	
04/30/2015 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Pending

	
124418-26092
	
PAZ-260CPHKDV5
	
HK
	
11106797.9
	
07/04/2011 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Published

	
124418-26402
	
PAZ-264CP
	
US
	
11/348608
	
02/06/2006 
	
8088755
	
01/03/2012 
	
11a, 12-DERIVATIVES OF TETRACYCLINE COMPOUNDS
	
Granted

	
124418-26403
	
PAZ-264CPCN
	
US
	
13/340040
	
12/29/2011 
	
8470804
	
06/25/2013 
	
11A, 12-DERIVATIVES OF TETRACYCLINE COMPOUNDS
	
Granted

	
124418-26404
	
PAZ-264CPCN
	
US
	
13/901525
	
05/23/2013 
	
 
	
 
	
11A, 12-DERIVATIVES OF TETRACYCLINE COMPOUNDS
	
Pending

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-26902
	
PAZ-269CPCN
	
US
	
12/462405
	
08/03/2009 
	
8436031
	
05/07/2013 
	
TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF
	
Granted

	
124418-28100
	
PAZ-0281CP
	
US
	
11/870317
	
10/10/2007 
	
8440646 B1
	
05/14/2013 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF BACILLUS ANTHRACIS INFECTIONS
	
Granted

	
124418-28101
	
PAZ-0281CPCN
	
US
	
13/893130
	
05/13/2013 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF BACILLUS ANTHRACIS INFECTIONS
	
Pending

	
124418-28502
	
PAZ-285
	
US
	
11/657412
	
01/24/2007 
	
9078811
	
07/14/2015 
	
METHODS OF INCREASING ORAL BIOAVAILABILITY OF TETRACYCLINES
	
Granted

	
124418-28503
	
PAZ-285CN
	
US
	
14/789506
	
07/01/2015 
	
 
	
 
	
METHODS OF INCREASING ORAL BIOAVAILABILITY OF TETRACYCLINES
	
Pending

	
124418-29102
	
PAZ-291CP
	
US
	
11/963509
	
12/21/2007 
	
8513223
	
08/20/2013 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
	
Granted

	
124418-29103
	
PAZ-291CPCN
	
US
	
13/987655
	
08/19/2013 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
	
Published

	
124418-29124
	
PAZ-291CPAU
	
AU
	
2007338681
	
06/30/2009 
	
2007338681
	
01/09/2014 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
	
Granted

	
124418-29126
	
PAZ-291CPCA
	
CA
	
2673486
	
06/19/2009 
	
2673486
	
09/08/2015 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
	
Granted

	
124418-29135
	
PAZ-291CPEP
	
EP
	
07870927.6
	
07/01/2009 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
	
Published

	
124418-29139
	
PAZ-291CPHK
	
HK
	
10104070.3
	
04/27/2010 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
	
Published

	
124418-29182
	
PAZ-291CPCADV
	
CA
	
2892739
	
05/25/2015 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
	
Published

	
124418-29203
	
PAZ-292CP
	
US
	
11/963540
	
12/21/2007 
	
8318706
	
11/27/2012 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-29204
	
PAZ-292CPDV
	
US
	
13/686639
	
11/27/2012 
	
9012433
	
04/21/2015 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Granted

	
124418-29206
	
PAZ-292CPDVCN
	
US
	
14/669238
	
03/26/2015 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Pending

	
124418-29224
	
PAZ-292CPAU
	
AU
	
2007338747
	
06/30/2009 
	
2007338747
	
04/03/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29225
	
PAZ-292CPBR
	
BR
	
P10720569-4
	
06/21/2009 
	
 
	
 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Published

	
124418-29226
	
PAZ-292CPCA
	
CA
	
2673466
	
06/19/2009 
	
 
	
 
	
SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Published

	
124418-29235
	
PAZ-292CPEP
	
EP
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29239
	
PAZ-292CPEPHK
	
HK
	
10103267.8
	
12/21/2007 
	
HK1135101
	
09/26/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29242
	
PAZ-292CPIL
	
IL
	
199483
	
06/21/2009 
	
199483
	
01/31/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-29243
	
PAZ-292CPJP
	
JP
	
2009-542938
	
06/19/2009 
	
5583411
	
07/25/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29244
	
PAZ-292CPILDV
	
IL
	
234755
	
09/21/2014 
	
 
	
 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Pending

	
124418-29245
	
PAZ-292CPHKDV1
	
HK
	
12110549.1
	
03/30/2010 
	
 
	
 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Published

	
124418-29246
	
PAZ-292CPKR
	
KR
	
10-2009-7015172
	
07/20/2009 
	
10-1538175
	
07/14/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29247
	
PAZ-292CPJPDV3
	
JP
	
2015-160343
	
08/17/2015 
	
 
	
 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Pending

	
124418-29248
	
PAZ-292CPMX
	
MX
	
MX/a/2009/006846
	
06/22/2009 
	
317114
	
01/13/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29250
	
PAZ-292CPDEDV
	
DE
	
12151178.6
	
01/13/2012 
	
2450347
	
06/24/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29251
	
PAZ-292CPESDV
	
ES
	
12151178.6
	
01/13/2012 
	
2450347
	
06/24/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29252
	
PAZ-292CPFRDV
	
FR
	
12151178.6
	
01/13/2012 
	
2450347
	
06/24/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29253
	
PAZ-292CPGBDV
	
GB
	
12151178.6
	
01/13/2012 
	
2450347
	
06/24/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29254
	
PAZ-292CPITDV
	
IT
	
12151178.6
	
01/13/2012 
	
2450347
	
06/24/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29259
	
PAZ-292CPLT
	
LT
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29261
	
PAZ-292CPMC
	
MC
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29262
	
PAZ-292CPLV
	
LV
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29264
	
PAZ-292CPAT
	
AT
	
07867938.8
	
07/09/2009 
	
AT E 652092
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29266
	
PAZ-292CPPL
	
PL
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29267
	
PAZ-292CPHU
	
HU
	
07867938.8
	
07/09/2009 
	
E07867938
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29268
	
PAZ-292CPEE
	
EE
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29269
	
PAZ-292CPCZ
	
CZ
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29270
	
PAZ-292CPDK
	
DK
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29271
	
PAZ-292CPSK
	
SK
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-29272
	
PAZ-292CPRO
	
RO
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29273
	
PAZ-292CPSI
	
SI
	
P-20073452
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29275
	
PAZ-292CPMT
	
MT
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29279
	
PAZ-292CPEPDV
	
EP
	
12151178.6
	
01/13/2012 
	
2450347
	
06/24/2015 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29280
	
PAZ-292CPCH
	
CH
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29281
	
PAZ-292CPDE
	
DE
	
07867938.8
	
07/09/2009 
	
602007035118.9
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29282
	
PAZ-292CPEPDV2
	
EP
	
12151177.8
	
01/31/2012 
	
 
	
 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Allowed

	
124418-29284
	
PAZ-292CPES
	
ES
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29285
	
PAZ-292CPFR
	
FR
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29286
	
PAZ-292CPGB
	
GB
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29287
	
PAZ-292CPTR
	
TR
	
07867938.8
	
07/09/2009 
	
TR 2014/05295 T4
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29289
	
PAZ-292CPIE
	
IE
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29290
	
PAZ-292CPIT
	
IT
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29291
	
PAZ-292CPLU
	
LU
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29292
	
PAZ-292CPPT
	
PT
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29293
	
PAZ-292CPNL
	
NL
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29294
	
PAZ-292CPIS
	
IS
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29296
	
PAZ-292CPFI
	
FI
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29297
	
PAZ-292CPBE
	
BE
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29298
	
PAZ-292CPSE
	
SE
	
07867938.8
	
07/09/2009 
	
2109602
	
02/12/2014 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Granted

	
124418-29299
	
PAZ-292CPJPDV2
	
JP
	
2014-121362
	
06/12/2014 
	
 
	
 
	
TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS
	
Published

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-29606
	
PAZ-296CP
	
US
	
12/102623
	
04/14/2008 
	
7935687
	
05/03/2011 
	
METHODS FOR TREATING SPINAL MUSCULAR ATROPHY USING TETRACYCLINE COMPOUNDS
	
Granted

	
124418-29607
	
PAZ-0296CPCN1
	
US
	
13/099993
	
05/03/2011 
	
8399437 B2
	
03/19/2013 
	
METHODS FOR TREATING SPINAL MUSCULAR ATROPHY USING TETRACYCLINE COMPOUNDS
	
Granted

	
124418-30503
	
PAZ-305CP
	
US
	
12/217709
	
07/07/2008 
	
 
	
 
	
METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS
	
Published

	
124418-30535
	
PAZ-305-1EP
	
EP
	
08826197.9
	
02/04/2010 
	
2176216
	
04/25/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-30539
	
PAZ-305HK
	
HK
	
10106266.2
	
06/25/2010 
	
1139386B
	
10/05/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-30582
	
PAZ-305-1 FR
	
FR
	
08826197.9
	
02/04/2010 
	
2176216
	
04/25/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-30583
	
PAZ-305-1 DE
	
DE
	
08826197.9
	
02/04/2010 
	
2176216
	
04/25/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-30584
	
PAZ-305-1 IT
	
IT
	
08826197.9
	
02/04/2010 
	
2176216
	
04/25/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-30585
	
PAZ-305-1 ES
	
ES
	
08826197.9
	
02/04/2010 
	
2176216
	
04/25/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-30586
	
PAZ-305-1 CH
	
CH
	
08826197.9
	
02/04/2010 
	
2176216
	
04/25/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-30587
	
PAZ-305-1 GB
	
GB
	
08826197.9
	
02/04/2010 
	
2176216
	
04/25/2012 
	
METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE
	
Granted

	
124418-31403
	
PAZ-314CP2
	
US
	
14/258847
	
04/22/2014 
	
 
	
 
	
MINOCYCLINE COMPOUNDS AND METHODS OF USE THEREOF
	
Published

	
124418-31502
	
PAZ-0315CP
	
US
	
12/414615
	
03/30/2009 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Published

	
124418-31523
	
PAZ-315-1 AR
	
AR
	
P20100101037
	
03/30/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Published

	
124418-31525
	
PAZ-315-1 BR
	
BR
	
PI0909211-0
	
09/28/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Pending

	
124418-31526
	
PAZ-315-1 CA
	
CA
	
2719751
	
11/24/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Published

	
124418-31527
	
PAZ-315-1 CL
	
CL
	
281-2010
	
03/29/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Pending

	
124418-31528
	
PAZ-315-1 CN
	
CN
	
200980119105.6
	
11/25/2010 
	
ZL200980119105.6
	
12/19/2012 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Granted

	
124418-31535
	
PAZ-315-1 EP
	
EP
	
09723896.8
	
10/14/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Published

	
124418-31540
	
PAZ-315-1 IN
	
IN
	
6812/CHENP/2010
	
10/22/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Published

	
124418-31546
	
PAZ-315-1 KR
	
KR
	
10-2010-7024076
	
10/27/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Pending

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-31561
	
PAZ-315-1 ZA
	
ZA
	
2010/07013
	
10/01/2010 
	
2010/07013
	
11/21/2013 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Granted

	
124418-31565
	
PAZ-315-1 TN
	
TN
	
TN2010/0445
	
09/24/2010 
	
21747
	
03/05/2012 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Granted

	
124418-31566
	
PAZ-315-1 UA
	
UA
	
a201012435
	
10/21/2010 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Allowed

	
124418-31577
	
PAZ-315-1JPDV
	
JP
	
2014-152471
	
07/28/2014 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Published

	
124418-31582
	
PAZ-315-1UADV
	
UA
	
a201505310
	
05/29/2015 
	
 
	
 
	
ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS
	
Pending

	
124418-32002
	
PAZ-320-1
	
US
	
12/471758
	
05/26/2009 
	
8383610 B2
	
02/26/2013 
	
SALTS AND POLYMORPHS OF 9-(2,2-DIMETHYLPROPYL-AMINOMETHYL) MINOCYCLINE
	
Granted

	
124418-32003
	
PAZ-320-1CPDV
	
US
	
13/749101
	
01/24/2013 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Allowed

	
124418-32023
	
PAZ-320-1 AR
	
AR
	
P090101875
	
05/26/2009 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32024
	
PAZ-320-1 AU
	
AU
	
2009248795
	
12/01/2010 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32025
	
PAZ-320-1 BR
	
BR
	
PI0913026-8
	
11/23/2010 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32026
	
PAZ-320-1 CA
	
CA
	
2724897
	
11/18/2010 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32027
	
PAZ-0320-1 01MC
	
MC
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32028
	
PAZ-320-1 CN
	
CN
	
200980129398.6
	
01/21/2011 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Allowed

	
124418-32030
	
PAZ-0320-1 01AT
	
AT
	
09751737.9
	
12/10/2010 
	
AT E 712971
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32031
	
PAZ-0320-1 01HU
	
HU
	
09751737.9
	
12/10/2010 
	
E09751737
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32035
	
PAZ-320-1 EP
	
EP
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32038
	
PAZ-320-1HKDV
	
HK
	
15105134.9
	
05/29/2015 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32039
	
PAZ-320-1 HK
	
HK
	
11109171.9
	
08/30/2011 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32040
	
PAZ-320-1 IN
	
IN
	
8287/CHENP/2010
	
12/20/2010 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32041
	
PAZ-320-1 ID
	
ID
	
W00201004382
	
12/17/2010 
	
 
	
01/23/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32042
	
PAZ-320-1 IL
	
IL
	
209414
	
11/18/2010 
	
209414
	
01/31/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-32043
	
PAZ-320-1 JP
	
JP
	
2011-510742
	
11/22/2010 
	
5727930
	
04/10/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32044
	
PAZ-320-1 JO
	
JO
	
3/2010
	
 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32045
	
PAZ-0320-01MT
	
MT
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32046
	
PAZ-320-1 KR
	
KR
	
10-2010-7028820
	
12/22/2010 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32047
	
PAZ-320-1 MY
	
MY
	
PI2010005445
	
12/02/2010 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32048
	
PAZ-320-1 MX
	
MX
	
MX/a/2010/012622
	
11/19/2010 
	
308008
	
03/19/2013 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32049
	
PAZ-0320-1 MK
	
MK
	
09751737.9
	
12/10/2010 
	
P-2015/273
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32050
	
PAZ-320-1 MA
	
MA
	
33447
	
12/20/2010 
	
32407
	
06/01/2011 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32051
	
PAZ-320-1 NZ
	
NZ
	
589574
	
11/29/2010 
	
589574
	
05/26/2009 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32052
	
PAZ-0320-1 01ES
	
ES
	
09751737.9
	
12/10/2010 
	
2538364
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32053
	
PAZ-0320-1 01CY
	
CY
	
09751737.9
	
12/10/2010 
	
CY20151100497
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32054
	
PAZ-0320-1NO
	
NO
	
09751737.9
	
12/10/2010 
	
2296464 B1
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32055
	
PAZ-320-1 PK
	
PK
	
440/2009
	
05/25/2009 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32056
	
PAZ-0320-1 01HR
	
HR
	
09751737.9
	
12/10/2010 
	
HR P20150584 T1
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32057
	
PAZ-320-1 PH
	
PH
	
1-2010-502624
	
11/23/2010 
	
1-2010-502624
	
06/20/2014 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32058
	
PAZ-320-1 RU
	
RU
	
2010152758
	
12/23/2010 
	
2500665
	
12/10/2013 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32059
	
PAZ-0320-1 01CY
	
LT
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32060
	
PAZ-320-1 SG
	
SG
	
201008531-4
	
11/22/2010 
	
166542
	
09/30/2013 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32061
	
PAZ-320-1 ZA
	
ZA
	
2010/08390
	
01/14/2014 
	
2010/08390
	
03/26/2014 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32062
	
PAZ-0320-1 01LV
	
LV
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32063
	
PAZ-320-1 TW
	
TW
	
098117308
	
05/25/2009 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-32064
	
PAZ-320-1 TH
	
TH
	
0901002307
	
05/25/2009 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32066
	
PAZ-0320-1 01PL
	
PL
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32067
	
PAZ-320-1 AE
	
AE
	
1166/2010
	
11/22/2010 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32068
	
PAZ-0320-1 01EE
	
EE
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32069
	
PAZ-0320-1 01CZ
	
CZ
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32070
	
PAZ-0320-1 01DK
	
DK
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32071
	
PAZ-0320-1 01SK
	
SK
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32072
	
PAZ-0320-1 01RO
	
RO
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32074
	
PAZ-0320-1 01BG
	
BG
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32076
	
PAZ-0320-1 01SI
	
SI
	
09751737.9
	
12/10/2010 
	
P-200931200
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32077
	
PAZ-320-1JPDV
	
JP
	
2015-076659
	
04/03/2015 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Pending

	
124418-32078
	
PAZ-320-1CNDV
	
CN
	
201510265009.X
	
05/22/2015 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32079
	
PAZ-320-1EPDV
	
EP
	
14156670.3
	
02/25/2014 
	
 
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Published

	
124418-32080
	
PAZ-0320-1 01CH
	
CH
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32081
	
PAZ-320-1 DE
	
DE
	
09751737.9
	
12/10/2010 
	
60200902990.2
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32082
	
PAZ-320-1 NZDV
	
NZ
	
598154
	
02/13/2012 
	
598154
	
09/03/2013 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32083
	
PAZ-320-1 LB
	
LB
	
557
	
01/28/2010 
	
8901
	
 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32085
	
PAZ-320-1 FR
	
FR
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32086
	
PAZ-320-1 GB
	
GB
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32087
	
PAZ-0320-1 01TR
	
TR
	
09751737.9
	
12/10/2010 
	
2015/06780
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32089
	
PAZ-0320-1 01IE
	
IE
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-32090
	
PAZ-320-1 IT
	
IT
	
09751737.9
	
12/10/2010 
	
5020155000019637
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32091
	
PAZ-0320-1 01LU
	
LU
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32092
	
PAZ-0320-1 01GR
	
GR
	
20150401137
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32093
	
PAZ-0320-1 01NL
	
NL
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32094
	
PAZ-0320-1 01IS
	
IS
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32096
	
PAZ-0320-1 01FI
	
FI
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32097
	
PAZ-0320-1 01BE
	
BE
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32098
	
PAZ-0320-1 01SE
	
SE
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-32099
	
PAZ-0320-1 01PT
	
PT
	
09751737.9
	
12/10/2010 
	
2296464
	
03/04/2015 
	
SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
	
Granted

	
124418-40024
	
PAZ-400CPAU
	
AU
	
2009292986
	
09/21/2009 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Pending

	
124418-40025
	
PAZ-400CPBR
	
BR
	
PI0918050-8
	
03/18/2011 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Pending

	
124418-40026
	
PAZ-400CPCA
	
CA
	
2737470
	
05/04/2011 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Published

	
124418-40035
	
PAZ-400CPEP
	
EP
	
09815349.7
	
04/08/2011 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Published

	
124418-40039
	
PAZ-400CPHK
	
HK
	
11113599.5
	
12/15/2011 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Published

	
124418-40046
	
PAZ-400CPKR
	
KR
	
10-2011-7008759
	
04/18/2011 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Pending

	
124418-40048
	
PAZ-400CPMX
	
MX
	
MX/a/2011/002780
	
03/15/2011 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Published

	
124418-40060
	
PAZ-400CPSG
	
SG
	
201101895-9
	
03/16/2011 
	
169701
	
09/13/2013 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Granted

	
124418-40061
	
PAZ-400CPZA
	
ZA
	
2011/01932
	
03/14/2011 
	
2011/01932
	
06/27/2012 
	
TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT
	
Granted

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-40402
	
PAZ-404
	
US
	
13/471275
	
05/14/2012 
	
 
	
 
	
CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-

CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME
	
Monitoring

	
124418-40426
	
PAZ-404CA
	
CA
	
2835876
	
11/12/2013 
	
 
	
 
	
CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME
	
Published

	
124418-40435
	
PAZ-404EP
	
EP
	
12782600.6
	
12/12/2013 
	
 
	
 
	
CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME
	
Published

	
124418-40439
	
PAZ-404HK
	
HK
	
14107977.6
	
08/04/2014 
	
 
	
 
	
CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME
	
Published

	
124418-40443
	
PAZ-404JP
	
JP
	
2014-510546
	
11/12/2013 
	
 
	
 
	
CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME
	
Published

	
124418-40501
	
PAZ-0405US
	
US
	
14/403616
	
11/25/2014 
	
 
	
 
	
7-DISUBSTITUTED-PHENYL TETRACYCLINE DERIVATIVES
	
Published

	
124418-40524
	
PAZ-405AU
	
AU
	
2013267397
	
11/26/2014 
	
 
	
 
	
7-DISUBSTITUTED-PHENYL TETRACYCLINE DERIVATIVES
	
Pending

	
124418-40526
	
PAZ-405CA
	
CA
	
2874640
	
11/24/2014 
	
 
	
 
	
7-DISUBSTITUTED-PHENYL TETRACYCLINE DERIVATIVES
	
Pending

	
124418-40535
	
PAZ-405EP
	
EP
	
13797512.4
	
12/10/2014 
	
 
	
 
	
7-DISUBSTITUTED-PHENYL TETRACYCLINE DERIVATIVES
	
Published

	
124418-40543
	
PAZ-405JP
	
JP
	
2015-515188
	
11/28/2014 
	
 
	
 
	
7-DISUBSTITUTED-PHENYL TETRACYCLINE DERIVATIVES
	
Published

	
124418-40602
	
PAZ-406US
	
US
	
14/414567
	
01/13/2015 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS
	
Published

	
124418-40624
	
PAZ-406AU
	
AU
	
2013289892
	
01/22/2015 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS
	
Pending

	
124418-40626
	
PAZ-406CA
	
CA
	
2878462
	
01/06/2015 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS
	
Pending

	
124418-40635
	
PAZ-406EP
	
EP
	
13816225.0
	
01/22/2015 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS
	
Published

	
124418-40643
	
PAZ-406JP
	
JP
	
2015-521878
	
01/09/2015 
	
 
	
 
	
TETRACYCLINE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS
	
Pending

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
[*]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[*]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
124418-44002
	
PAZ-440
	
US
	
13/893717
	
05/14/2013 
	
 
	
 
	
METHODS OF USING (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE
	
Monitoring

	
124418-44024
	
PAZ-440AU
	
AU
	
2013262991
	
11/12/2014 
	
 
	
 
	
METHODS OF USING (4S,4AS,5AR,12AS)-4 DIMETHYLAMINO,3-10,12,12A-TETRAHYDROXY-7-[(METHOXY (METHYL) AMINO)-METHYL] -1,11-DIOXO-1,4,4A,5.5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE
	
Pending

	
124418-44026
	
PAZ-440CA
	
CA
	
2873412
	
11/12/2014 
	
 
	
 
	
METHODS OF USING (4S,4AS,5AR,12AS)-4 DIMETHYLAMINO,3-10,12,12A-TETRAHYDROXY-7-[(METHOXY (METHYL) AMINO)-METHYL] -1,11-DIOXO-1,4,4A,5.5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE
	
Pending

	
124418-44035
	
PAZ-440EP
	
EP
	
13790638.4
	
11/21/2014 
	
 
	
 
	
METHODS OF USING (4S,4AS,5AR,12AS)-4 DIMETHYLAMINO,3-10,12,12A-TETRAHYDROXY-7-[(METHOXY (METHYL) AMINO)-METHYL] -1,11-DIOXO-1,4,4A,5.5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE
	
Published

	
124418-44043
	
PAZ-440JP
	
JP
	
2015-512752
	
11/12/2014 
	
 
	
 
	
METHODS OF USING (4S,4AS,5AR,12AS)-4 DIMETHYLAMINO,3-10,12,12A-TETRAHYDROXY-7-[(METHOXY (METHYL) AMINO)-METHYL] -1,11-DIOXO-1,4,4A,5.5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE
	
Published

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
Country
	
Matter No.
	
Title
	
Serial No.
	
Filing Date
	
Patent No.
	
Grant Date
	
Expiration Date
	
Status

	
United States
	
0872521-00001
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
	
11/060,641
	
16-Feb-05
	
7,658,945
	
09-Feb-10
	
15-Apr-27
	
Issued

	
Australia
	
0872521-00005
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF 
	
2005215782
	
16-Feb-05
	
2005215782
	
11-Aug-11
	
16-Feb-25
	
Issued

	
Brazil
	
0872521-00006
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF 
	
PI0507733-8
	
16-Feb-05
	
 
	
 
	
 
	
Pending

	
Canada
	
0872521-00007
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF 
	
2556450
	
16-Feb-05
	
2556450
	
06-Aug-13
	
16-Feb-25
	
Issued

	
China P.R.
	
0872521-00008
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
	
200580008195.3
	
16-Feb-05
	
200580008195.3
	
14-Oct-09
	
15-Feb-25
	
Issued

	
Israel
	
0872521-00010
	
COMPOSITIONS COMPRISING ZOLPIDEM FOR DELIVERING A HYPNOTIC AGENT ACROSS THE ORAL MUCOSA FOR TREATING INSOMNIA
	
177227
	
16-Feb-05
	
177227
	
31-Aug-13
	
16-Feb-25
	
Issued

	
India
	
0872521-00011
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF 
	
2493/KOLNP/2006
	
16-Feb-05
	
 
	
 
	
 
	
Pending

	
Japan
	
0872521-00012
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF  
	
2006-553364
	
16-Feb-05
	
5179757
	
18-Jan-13
	
16-Feb-25
	
Issued

	
Mexico
	
0872521-00014
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF 
	
PA/a/2006/009296
	
16-Feb-05
	
277300
	
14-Jul-10
	
16-Feb-25
	
Issued

	
New Zealand
	
0872521-00015
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF 
	
548856
	
16-Feb-05
	
548856
	
11-Feb-10
	
16-Feb-25
	
Issued

	
Singapore
	
0872521-00016
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
	
200605156-9
	
16-Feb-05
	
124564
	
29-May-09
	
16-Feb-25
	
Issued

	
South Africa
	
0872521-00017
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF 
	
2006/06411
	
16-Feb-05
	
2006/06411
	
28-May-08
	
16-Feb-25
	
Issued

	
United States
	
0872521-00024
	
METHODS OF TREATING MIDDLE-OF-THE NIGHT INSOMNIA
	
11/439,874
	
23-May-06
	
8242131
	
14-Aug-12
	
20-Aug-29
	
Issued

	
United States
	
0872521-00050
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
	
11/833,323
	
03-Aug-07
	
7,682,628
	
23-Mar-10
	
16-Feb-25
	
Issued

	
New Zealand
	
0872521-00062
	
SOLID COMPOSITIONS AND METHODS FOR TREATING MIDDLE-0F-THE NIGHT INSOMNIA
	
563979
	
23-May-06
	
563979
	
07-Jun-11
	
23-May-26
	
Issued

	
South Africa
	
0872521-00063
	
COMPOSITIONS AND METHODS FOR TREATING MIDDLE-0F-THE NIGHT INSOMNIA
	
2007/10205
	
23-May-06
	
2007/10205
	
25-Mar-09
	
23-May-26
	
Issued

	
China P.R.
	
0872521-00064
	
SOLID COMPOSITIONS AND METHODS FOR TREATING MIDDLE-0F-THE NIGHT INSOMNIA
	
200680021133.0
	
23-May-06
	
200680021133.0
	
20-Jun-12
	
22-May-26
	
Issued

	
Hong Kong
	
0872521-00065
	
SOLID COMPOSITIONS AND METHODS FOR TREATING MIDDLE-0F-THE NIGHT INSOMNIA
	
08109311.5
	
20-Aug-08
	
HK1118203
	
08-Mar-13
	
23-May-26
	
Issued

	
Singapore
	
0872521-00069
	
SOLID COMPOSITIONS AND METHODS FOR TREATING MIDDLE-0F-THE NIGHT INSOMNIA
	
200718003-7
	
23-May-06
	
137547
	
31-Mar-11
	
23-May-26
	
Issued

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
Country
	
Matter No.
	
Title
	
Serial No.
	
Filing Date
	
Patent No.
	
Grant Date
	
Expiration Date
	
Status

	
Mexico
	
0872521-00070
	
COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE NIGHT INSOMNIA
	
MX/a/2007/014679
	
23-May-06
	
307563
	
27-Feb-13
	
23-May-26
	
Issued

	
Brazil
	
0872521-00071
	
COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE NIGHT INSOMNIA
	
PI0609984-0
	
23-May-06
	
 
	
 
	
 
	
Pending

	
United States
	
0872521-00097
	
COMPOSITIONS FOR TREATING INSOMNIA
	
12/795,934
	
08-Jun-10
	
8252809
	
28-Aug-12
	
16-Feb-25
	
Issued

	
Australia
	
0872521-00131
	
SOLID COMPOSITIONS AND METHODS FOR TREATING MIDDLE-0F-THE NIGHT INSOMNIA
	
2012238306
	
10-Oct-12
	
 
	
 
	
 
	
Pending

	
Canada
	
0872521-00137
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
	
2816904
	
14-Jun-13
	
 
	
 
	
 
	
Pending

	
Israel
	
0872521-00140
	
COMPOSITIONS AND METHODS FOR TREATING MIDDLE-0F-THE NIGHT INSOMNIA
	
229039
	
23-May-06
	
 
	
 
	
 
	
Pending

	
United States
	
0872521-00142
	
COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF
	
14/253,241
	
15-Apr-14
	
 
	
 
	
 
	
Pending

	
United States
	
0872521-00145
	
COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE-NIGHT INSOMNIA 
	
14/567,922
	
11-Dec-14
	
 
	
 
	
 
	
Pending

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
	

EXHIBIT D

	
PARATEK PHARMACEUTICALS, INC. TRADEMARK PORTFOLIO

	
CONFIDENTIAL

 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
McCarter Ref.
	
Trademark
	
Country
	
Appln. No.
	
Filing Date
	
Reg. No.
	
Reg. Date
	
Status

	
124418-91600
	
BAKTORA
	
US
	
86664421
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91635
	
BAKTORA
	
EP Comm.
	
014294482
	
06/25/2015 
	
 
	
 
	
Published

	
124418-91000
	
Hexagon Design
	
US
	
86645379
	
05/29/2015 
	
 
	
 
	
Pending

	
124418-91400
	
INVYSTEX
	
US
	
86664440
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91435
	
INVYSTEX
	
EP Comm.
	
014294441
	
06/25/2015 
	
 
	
 
	
Published

	
124418-91300
	
INVYSTYX
	
US
	
86664444
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91335
	
INVYSTYX
	
EP Comm.
	
014294433
	
06/25/2015 
	
 
	
 
	
Published

	
124418-91800
	
IRADIKO
	
US
	
86664402
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91835
	
IRADIKO
	
EP Comm.
	
014294524
	
06/25/2015 
	
 
	
 
	
Published

	
124418-91900
	
IRADYFEX
	
US
	
86664392
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91935
	
IRADYFEX
	
EP Comm.
	
014294541
	
06/25/2015 
	
 
	
 
	
Published

	
124418-91200
	
IRADYKO
	
US
	
86664451
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91235
	
IRADYKO
	
EP Comm.
	
014294425
	
06/25/2015 
	
 
	
 
	
Published

	
124418-91700
	
NUALTO
	
US
	
86664413
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91735
	
NUALTO
	
EP Comm.
	
014294508
	
06/25/2015 
	
 
	
 
	
Published

	
124418-91500
	
ODACYUS
	
US
	
86664433
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91535
	
ODACYUS
	
EP Comm.
	
014294466
	
06/25/2015 
	
 
	
 
	
Published

	
124418-90735
	
PARACYCLINE
	
EP Comm.
	
001561687
	
03/16/2000 
	
001561687
	
05/18/2001 
	
Registered

	
124418-90743
	
PARACYCLINE
	
JP
	
2000-026596
	
03/17/2000 
	
4447298
	
01/19/2001 
	
Registered

	
124418-90100
	
PARATEK
	
US
	
86380676
	
08/29/2014 
	
4716271
	
04/07/2015 
	
Registered

	
124418-90300
	
PARATEK
	
US
	
86496998
	
01/07/2015 
	
 
	
 
	
Pending

	
124418-90325
	
PARATEK
	
BR
	
909645213
	
07/07/2015 
	
 
	
 
	
Pending

	
124418-90325
	
PARATEK
	
BR
	
909645272
	
07/07/2015 
	
 
	
 
	
Pending

	
124418-90326
	
PARATEK
	
CA
	
1735917
	
07/06/2015 
	
 
	
 
	
Pending

	
124418-90328
	
PARATEK
	
CN
	
 
	
07/07/2015 
	
 
	
 
	
Pending

	
124418-90335
	
PARATEK
	
EP Comm.
	
014333074
	
07/03/2015 
	
 
	
 
	
Published

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
124418-90343
	
PARATEK
	
JP
	
2015-063788
	
07/06/2015 
	
 
	
 
	
Pending

	
124418-90346
	
PARATEK
	
KR
	
45-2015-6168
	
07/06/2015 
	
 
	
 
	
Pending

	
124418-90360
	
PARATEK
	
SG
	
40201511648U
	
07/07/2015 
	
 
	
 
	
Pending

	
124418-90360
	
PARATEK
	
SG
	
40201511649Y
	
07/07/2015 
	
 
	
 
	
Pending

	
124418-90363
	
PARATEK
	
TW
	
104039032
	
07/07/2015 
	
 
	
 
	
Pending

	
124418-90800
	
PARATEK (+ Hexagon) B&W
	
US
	
86645393
	
05/29/2015 
	
 
	
 
	
Pending

	
124418-90900
	
PARATEK (+ Hexagon) Color
	
US
	
86645386
	
05/29/2015 
	
 
	
 
	
Pending

	
124418-90200
	
PARATEK PHARMACEUTICALS Logo
	
US
	
86378684
	
08/27/2014 
	
4751074
	
06/09/2015 
	
Registered

	
124418-90400
	
PARATEK PHARMACEUTICALS Logo
	
US
	
86497006
	
01/07/2015 
	
 
	
 
	
Pending

	
124418-90535
	
PARATEK PHARMACEUTICALS Logo
	
EP Comm.
	
002520427
	
01/02/2002 
	
002520427
	
07/28/2003 
	
Registered

	
124418-92900
	
PARATEK POSITIVE PATIENT STORIES
	
US
	
86664460
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-91100
	
POSITIVE PATIENT STORIES
	
US
	
86664467
	
06/16/2015 
	
 
	
 
	
Pending

	
124418-90635
	
THE ANTIBIOTIC RESISTANCE COMPANY
	
EP Comm.
	
001654797
	
05/15/2000 
	
001654797
	
06/19/2001 
	
Registered

	
124418-90643
	
THE ANTIBIOTIC RESISTANCE COMPANY
	
JP
	
2000-054156
	
05/18/2000 
	
4460371
	
03/16/2001 
	
Registered

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT D

PARATEK PHARMACEUTICALS, INC. COPYRIGHTS

NONE

 

EXHIBIT D

PARATEK PHARMACEUTICALS, INC. LICENSES

 

	
 
	
1)
	
Tufts University License Agreement with Paratek Pharmaceuticals, Inc. dated February 1, 1997, and subsequent Amendments 1 through 9 thereto.

	
 
	
2)
	
Collaborative Research and License Agreement between Warner Chilcott Company, Inc. (now Allergan plc) and Paratek Pharmaceuticals, Inc. dated July 2, 2007.

	
 
	
3)
	
Cooperative Research and Development Agreement for Material Transfer between U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Paratek Pharmaceuticals, Inc. dated June 4, 2012. 

	
 
	
4)
	
U.S. License and Collaboration Agreement between Transcept Pharmaceuticals, Inc. (now Paratek Pharmaceuticals, Inc.) and Purdue Pharmaceuticals Products L.P. dated July 31, 2009.  

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT E:

 

BORROWER’S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS

 

 

				
	
Institution Name and Address
	
Account Number
	
Average Balance in Account
	
Name of Account Owner

	
     Bank of America
	
[____] 
	
     $[____]
	
Paratek Pharma, LLC

	
     Bank of America
	
[____]
	
     $[____]
	
Paratek Pharma, LLC

	
     Bank of America
	
[____]
	
     $[____]
	
Paratek Securities Corporation

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT F

COMPLIANCE CERTIFICATE

Hercules Technology Growth Capital, Inc. 
400 Hamilton Avenue, Suite 310
Palo Alto, CA 94301

Reference is made to that certain Loan and Security Agreement dated September 30, 2015 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the “Loan Agreement”) by and among Hercules Technology Growth Capital, Inc., the several banks and other financial institutions or entities from time to time party thereto (collectively, the “Lender”) and Hercules Technology Growth Capital, Inc., as agent for the Lender (the “Agent”) and Paratek Pharmaceuticals, Inc. and Paratek Pharma, LLC (individually and collectively, jointly and severally, the “Borrower”) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.

The undersigned is an Officer of Borrower, knowledgeable of all Borrower financial matters, and is authorized to provide certification of information regarding Borrower; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, except as set forth below, (i) Borrower is in compliance for the period ending ___________ of all covenants, conditions and terms and (ii) hereby reaffirms that all representations and warranties contained therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties.  Attached are the required documents supporting the above certification.  The undersigned further certifies that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year end adjustments) and are consistent from one period to the next except as explained below.

EXCEPTION(S):___________________________________________________________________________________________________________________________________________________________________________________________________________________________

			
	
REPORTING REQUIREMENT
	
REQUIRED
	
CHECK IF ATTACHED

	
Interim Financial Statements 
	
Monthly within 30 days
	
 

	
Interim Financial Statements 
	
Quarterly within 45 days
	
 

	
Audited Financial Statements 
	
FYE within 90 days
	
 

	
 
	
 
	
 

	
FINANCIAL COVENANT
	
REQUIRED
	
ACTUAL

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
Liquidity
	
Lesser of (i) one (1) times the outstanding Secured Obligations of Borrower to Lender or (ii) one hundred 

percent (100%) of all cash of Borrower and its Subsidiaries (other than cash held in (a) Excluded Accounts or (b) other accounts in an aggregate amount not in excess of One Hundred Thousand Dollars ($100,000.00)).
	
 

 

 

 

			
	
INELIGIBLE SUBSIDIARIES
	
 
	
 

	
Name of Ineligible Subsidiary
	
Value of Assets 
	
Annual Revenue

	
 
	
 
	
 

	
 
	
 
	
 

	
 
	
 
	
 

 

 

 

		
	
Very Truly Yours,

	
PARATEK PHARMACEUTICALS, INC.

	
By:
	
 

	
Name:
	
 

	
Title:
	
 

	
 

	
PARATEK PHARMA, LLC

	
By:
	
 

	
Name:
	
 

	
Title:
	
 

 

 

 

(Signature page to Compliance Certificate)

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT G

FORM OF JOINDER AGREEMENT

This Joinder Agreement (the “Joinder Agreement”) is made and dated as of [          ], 20[  ], and is entered into by and between [_______________], a [_________] (“Subsidiary”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (as “Agent”).  

RECITALS

A.  Subsidiary’s Affiliates, PARATEK PHARMACEUTICALS, INC. and PARAKTEK PHARMA, LLC (individually and collectively, jointly and severally, the “Borrower”) [have entered/desire to enter] into that certain Loan and Security Agreement dated September 30, 2015, with the several banks and other financial institutions or entities from time to time party thereto as lender (collectively, the “Lender”) and Agent, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith; 

B.  Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Borrower’s execution of the Loan Agreement and the other agreements executed and delivered in connection therewith;

AGREEMENT

NOW THEREFORE, Subsidiary and Agent agree as follows:

	
1.
	
The recitals set forth above are incorporated into and made part of this Joinder Agreement.  Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement.

	
2.
	
 By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that (a) with respect to (i) Section 5.1 of the Loan Agreement, Subsidiary represents that it is an entity duly organized, legally existing and in good standing under the laws of [        ], (b) neither Agent nor Lender shall have any duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, (c) that if Subsidiary is covered by Borrower’s insurance, Subsidiary shall not be required to maintain separate insurance or comply with the provisions of Sections 6.1 and 6.2 of the Loan Agreement, and (d) that as long as Borrower satisfies the requirements of Section 7.1 of the Loan Agreement, Subsidiary shall not have to provide Agent separate Financial Statements.  To the extent that Agent or Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties, responsibilities or obligations shall flow only to Borrower and not to Subsidiary or any other Person or entity.  By way of example (and not an exclusive list): (i) Agent’s providing notice to Borrower in accordance with the Loan Agreement or as otherwise agreed among Borrower, Agent and Lender shall be deemed provided to Subsidiary; (ii) a Lender’s providing an Advance to Borrower shall be deemed an Advance to Subsidiary; and (iii) Subsidiary shall have no right to request an Advance or make any other demand on Lender.

	
3.
	
Subsidiary agrees not to certificate its equity securities without Agent’s prior written consent, which consent may be conditioned on the delivery of such equity securities to Agent in order to perfect Agent’s security interest in such equity securities.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	
4.
	
Subsidiary acknowledges that it benefits, both directly and indirectly, from the Loan Agreement, and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee for the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy proceeding) to the fullest extent provided by law, any and all claims, rights or defenses to the enforcement of this Joinder Agreement on the basis that (a) it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b) its obligations under this Joinder Agreement are avoidable as a fraudulent conveyance. 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

[SIGNATURE PAGE TO JOINDER AGREEMENT]

SUBSIDIARY:

[_________________________________]

	
 
	

	
 

	
 
	

	
By:

	
 
	

	
Name:

	
 
	

	
Title: 

	
 
	

	
Address:

	
 
	

	
              ________________________

	
 
	

	
Telephone: 

	
 
	

	
Facsimile: 

AGENT:

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

By:____________________________________
Name:__________________________________
Title: ___________________________________

Address:
400 Hamilton Ave., Suite 310
Palo Alto, CA 94301
Facsimile:  650-473-9194
Telephone:  650-289-3060

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

EXHIBIT h

ACH DEBIT AUTHORIZATION AGREEMENT

Hercules Technology Growth Capital, Inc. 
400 Hamilton Avenue, Suite 310
Palo Alto, CA  94301

Re:  Loan and Security Agreement dated September 30, 2015  (the “Agreement”) by and among Paratek Pharmaceuticals, Inc. and Paratek Pharma, LLC (individually and collectively, jointly and severally, the “Borrower”) and Hercules Technology Growth Capital, Inc., as agent (“Agent”) and the lenders party thereto (collectively, the “Lender”)

In connection with the above referenced Agreement, Borrower hereby authorizes Agent to initiate debit entries for (i) the periodic payments due under the Agreement and (ii) after prior notice to Borrower, out-of-pocket legal fees and costs incurred by Agent or Lender pursuant to Section 11.11 of the Agreement to Borrower’s account indicated below.  Borrower authorizes the depository institution named below to debit to such account.

 

 

		
	
Depository Name
	
Branch

	
City
	
State and Zip Code

	
Transit/ABA Number
	
Account Number

This authority will remain in full force and effect so long as any amounts are due under the Agreement. 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

PARATEK PHARMACEUTICALS, INC.

____________________________________________
(Borrower)(Please Print)

By: _________________________________________

Date: ________________________________________

 

 

PARATEK PHARMA, LLC

____________________________________________
(Borrower)(Please Print)

By: _________________________________________

Date: ________________________________________

 

 

(Signature page to ACH Debit Authorization Agreement)

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Acknowledged and agreed to:

 

AGENT:

HERCULES TECHNOLOGY
GROWTH CAPITAL, INC.

By:_____________________________
Name:__________________________
Title:___________________________

 

 

LENDER:

HERCULES TECHNOLOGY
GROWTH CAPITAL, INC.

By:_____________________________
Name:__________________________
Title:___________________________

 

Address:

400 Hamilton Ave., Suite 310
Palo Alto, CA 94301
Facsimile: (650) 473-9194
Telephone: (650) 289-3060

 

 

 

 

(Signature page to ACH Debit Authorization Agreement)

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 1.1

COMMITMENTS

		
	
LENDER
	
TERM COMMITMENT

	
HERCULES TECHNOLOGY II, L.P.
	
$20,000,000

	
HERCULES TECHNOLOGY III, L.P.
	
$20,000,000

	
TOTAL COMMITMENTS
	
$40,000,000

 

 

 

1880637.9\27955.00050

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 1

 

SUBSIDIARIES

 

		
	
NAME
	
JURISDICTION

	
Paratek Pharma, LLC
	
Delaware

	
Partek Securities Corporation   
	
MA

	
Transcept Pharma, Inc.    
	
Delaware     

	
Paratek UK Limited
	
UK

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 1A

 

EXISTING PERMITTED INDEBTEDNESS

 

 

	
 
	
(1)
	
Letter of credit in the amount of $250,000 issued by Bank of America, securing the Borrower’s lease. 

 

	
 
	
(2)
	
Borrower’s Bank of America credit card program.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 1B

 

EXISTING PERMITTED INVESTMENTS

 

 

	
 
	
(1)
	
Paratek Securities Corporation 

BofA Government Plus Reserves 4151

Balance at 9/28/15: $75,010,193

 

	
 
	
(2)
	
Investments in Paratek UK Limited outstanding as of the date hereof.  

 

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 1C

 

EXISTING PERMITTED LIENS

 

 

	
 
	
(1)
	
Cash collateral securing the letter of credit referenced in Schedule 1A.

 

 

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 5.3

 

CONSENTS, ETC.

 

 

None.

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 5.5

 

ACTIONS BEFORE GOVERNMENTAL AUTHORITIES

 

None. 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 5.8

 

TAX MATTERS

 

None.

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 5.9

 

INTELLECTUAL PROPERTY CLAIMS

None.

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 5.10

 

INTELLECTUAL PROPERTY

 

None.

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 5.11

 

BORROWER PRODUCTS

 

 

 

[*]

 

The United States District Court for the District of New Jersey, or the District Court, held a consolidated trial between December 1, 2014 and December 15, 2014 involving Paratek, Purdue, and their patent infringement claims against Allergan Elizabeth, Novel, and Dr. Reddy’s. The District Court then received post-trial briefing and held a February 13, 2015 post-trial hearing. On March 27, 2015, the District Court issued an order and accompanying opinion finding that: (a) the asserted claims of U.S. Patent Nos. 7,682,628, 8,242,131, and 8,252,809, together, the “’628, ‘131, and ‘809 patents, are invalid as obvious; (b) Allergan Elizabeth, Novel, and Dr. Reddy’s infringe the ‘131 patent; (c) Novel infringes the ‘628 patent; and (d) Novel and Dr. Reddy’s infringe the ‘809 patent. On April 9, 2015, the District Court entered final judgment consistent with the March 27, 2015 opinion and order referenced above.  As a result of the District Court’s findings, the intangible assets representing Intermezzo product rights have been impaired and the related contingent obligation has been reduced in light of an expected decline in Intermezzo sales. 

 

The Company and Purdue jointly appealed the District Court’s final judgment to the United States Court of Appeals for the Federal Circuit on May 6, 2015.  On July 13, 2015, the Company and Purdue filed their opening brief in the appeal. The appeal is pending.  

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

SCHEDULE 5.14 

 

CAPITALIZATION

 

 

 

		
	
NAME
	
JURISDICTION

	
Paratek Pharma, LLC
	
Delaware

	
Partek Securities Corporation   
	
MA

	
Transcept Pharma, Inc.    
	
Delaware     

	
Paratek UK Limited
	
UK

 

 

 

 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]